CN116725958A - A kind of thiolated oxidized guar gum/sodium alginate microsphere and its preparation method and application - Google Patents
A kind of thiolated oxidized guar gum/sodium alginate microsphere and its preparation method and application Download PDFInfo
- Publication number
- CN116725958A CN116725958A CN202310640431.3A CN202310640431A CN116725958A CN 116725958 A CN116725958 A CN 116725958A CN 202310640431 A CN202310640431 A CN 202310640431A CN 116725958 A CN116725958 A CN 116725958A
- Authority
- CN
- China
- Prior art keywords
- guar gum
- microspheres
- lgg
- sodium alginate
- microsphere
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/238—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from seeds, e.g. locust bean gum or guar gum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/256—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from seaweeds, e.g. alginates, agar or carrageenan
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0087—Glucomannans or galactomannans; Tara or tara gum, i.e. D-mannose and D-galactose units, e.g. from Cesalpinia spinosa; Tamarind gum, i.e. D-galactose, D-glucose and D-xylose units, e.g. from Tamarindus indica; Gum Arabic, i.e. L-arabinose, L-rhamnose, D-galactose and D-glucuronic acid units, e.g. from Acacia Senegal or Acacia Seyal; Derivatives thereof
- C08B37/0096—Guar, guar gum, guar flour, guaran, i.e. (beta-1,4) linked D-mannose units in the main chain branched with D-galactose units in (alpha-1,6), e.g. from Cyamopsis Tetragonolobus; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Dispersion Chemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
技术领域Technical field
本发明属于生物医用材料领域,具体涉及一种巯基化氧化瓜尔豆胶/海藻酸钠微球及其制备方法与应用。The invention belongs to the field of biomedical materials, and specifically relates to a thiolated oxidized guar gum/sodium alginate microsphere and its preparation method and application.
背景技术Background technique
公开该背景技术部分的信息仅仅旨在增加对本发明的总体背景的理解,而不必然被视为承认或以任何形式暗示该信息构成已经成为本领域一般技术人员所公知的现有技术。The information in this Background section is disclosed solely for the purpose of increasing understanding of the general background of the invention and is not necessarily considered to be an admission or in any way implying that the information constitutes prior art that is already known to a person of ordinary skill in the art.
炎症性肠病(Inflammatory bowel diseases,IBD)是伴有腹痛、腹泻、便血和体重下降等症状的肠道慢性疾病,严重威胁着人类健康。IBD已成为一个全球性的公共卫生问题。尽管该疾病的发病机制尚不清楚,但肠道微生物群与炎症特征之间存在潜在关联。益生菌可以通过调节免疫功能,产生有机酸以及抗菌化合物对机体起到益生作用。然而,由于益生菌通过口服进入消化道后易受胃酸的低pH、胆汁等不利因素的影响,导致益生菌到达肠道的存活率下降,很难有足够量的益生菌到达肠道定植,进而发挥益生作用。目前,微球是包埋益生菌最有效的技术之一。微球可以显著增强益生菌对恶劣环境的耐受力,从而增加益生菌到达肠道的活菌数量。虽然益生菌通过微球包埋在模拟胃液中可以提高存活率,但是其在肠道中粘附性差。因此迫切需要开发具有耐胃酸、肠道靶向和肠道黏附定植功能的新型给药系统。Inflammatory bowel diseases (IBD) are chronic intestinal diseases accompanied by symptoms such as abdominal pain, diarrhea, bloody stools, and weight loss, which seriously threaten human health. IBD has become a global public health problem. Although the pathogenesis of the disease remains unclear, there is a potential association between the gut microbiota and inflammatory signatures. Probiotics can play a beneficial role in the body by regulating immune function and producing organic acids and antibacterial compounds. However, since probiotics are easily affected by adverse factors such as low pH of gastric acid and bile after entering the digestive tract through oral administration, the survival rate of probiotics reaching the intestinal tract is reduced, and it is difficult for a sufficient amount of probiotics to reach the intestinal colon and colonize. exert a probiotic effect. Currently, microspheres are one of the most effective technologies for encapsulating probiotics. Microspheres can significantly enhance the tolerance of probiotics to harsh environments, thereby increasing the number of viable bacteria that reach the intestinal tract. Although encapsulation of probiotics in simulated gastric juice through microspheres can improve the survival rate, their adhesion in the intestine is poor. Therefore, there is an urgent need to develop new drug delivery systems with gastric acid resistance, intestinal targeting, and intestinal adhesive colonization functions.
发明内容Contents of the invention
为了解决现有技术的不足,本发明的目的是提供一种巯基化氧化瓜尔豆胶/海藻酸钠微球及其制备方法与应用,本发明以巯基化氧化瓜尔豆胶和海藻酸钠为基材,通过乳化凝胶法制备构建了具有耐胃酸、结肠靶向和肠道黏附性的微球,利用微球技术对益生菌进行包埋,提高益生菌在胃液的存活率和肠道黏附性。In order to solve the deficiencies of the prior art, the purpose of the present invention is to provide a thiolated oxidized guar gum/sodium alginate microsphere and its preparation method and application. The present invention uses thiolated oxidized guar gum and sodium alginate. As the base material, microspheres with gastric acid resistance, colon targeting and intestinal adhesion were prepared and constructed through the emulsification gel method. Microsphere technology was used to encapsulate probiotics and improve the survival rate of probiotics in gastric juice and intestinal tract. Adhesion.
为了实现上述目的,本发明的技术方案为:In order to achieve the above objects, the technical solution of the present invention is:
本发明的第一个方面,提供一种巯基化氧化瓜尔豆胶/海藻酸钠微球的制备方法,包括如下步骤:A first aspect of the invention provides a method for preparing thiolated oxidized guar gum/sodium alginate microspheres, which includes the following steps:
S1、通过对GG进行TEMPO氧化反应得到OGG,通过酰胺化反应将L-cys接枝到OGG分子链上生成SOGG;S1. OGG is obtained by performing TEMPO oxidation reaction on GG, and L-cys is grafted onto the OGG molecular chain through amidation reaction to generate SOGG;
S2、配置含SOGG、SA和碳酸钙的混合液,向混合液中加入菌悬液并搅匀,得到水相;配置含司盘80的液体石蜡溶液,司盘80充分溶解,得到油相;将水相缓慢加入油相中,乳化,搅拌形成W/O液滴后,加入冰醋酸继续搅拌,使固化;破乳,静置,离心,除去油相,收集得到巯基化氧化瓜尔豆胶/海藻酸钠微球,简称LGG微球。S2. Prepare a mixed solution containing SOGG, SA and calcium carbonate, add bacterial suspension to the mixed solution and stir well to obtain a water phase; prepare a liquid paraffin solution containing Span 80, and fully dissolve Span 80 to obtain an oil phase; Slowly add the water phase into the oil phase, emulsify, stir to form W/O droplets, add glacial acetic acid and continue stirring to solidify; break the emulsification, let stand, centrifuge, remove the oil phase, and collect to obtain thiolated oxidized guar gum. /Sodium alginate microspheres, referred to as LGG microspheres.
本发明的第二个方面,提供一种巯基化氧化瓜尔豆胶/海藻酸钠微球,所述巯基化氧化瓜尔豆胶/海藻酸钠微球由上述制备方法制得。A second aspect of the present invention provides a thiolated oxidized guar gum/sodium alginate microsphere, which is prepared by the above preparation method.
本发明的第三个方面,提供上述的一种巯基化氧化瓜尔豆胶/海藻酸钠微球在生物医用材料领域中的应用。A third aspect of the present invention provides the application of the above-mentioned thiolated oxidized guar gum/sodium alginate microspheres in the field of biomedical materials.
本发明的有益效果为:The beneficial effects of the present invention are:
目前鲜少有人报道关于改性GG包埋益生菌进行肠道靶向的研究。GG是一种天然高分子多糖,价格低廉,生物相容性好,且无毒,本发明通过酰胺化反应制备出SOGG,为GG的应用提供新的思路。At present, few studies on intestinal targeting of modified GG-encapsulated probiotics have been reported. GG is a natural polymer polysaccharide with low price, good biocompatibility and non-toxicity. The present invention prepares SOGG through amidation reaction, which provides new ideas for the application of GG.
本发明通过对天然高分子多糖GG进行TEMPO体系氧化,再通过酰胺键将L-cys接枝改性,制备了具有巯基的SOGG。采用乳化凝胶法,利用SOGG和SA交联负载LGG构建了LGG微球。该LGG微球具有良好的生物相容性。本发明利用了SOGG的巯基可以自氧化形成二硫键和SA与Ca2+离子成胶的特性,制备了具有双网络交联微球。该微球具有肠道黏附性和耐胃酸,可提高LGG在胃内的存活率;微球上的巯基起到了连接益生菌和肠道粘液的作用,增加了益生菌在肠道的定植粘附,有利于益生菌在肠道内发挥益生作用。本发明为益生菌在奶制品、饮料和医药行业的应用提供理论依据。The present invention prepares SOGG with thiol groups by oxidizing the natural polymer polysaccharide GG in a TEMPO system and then grafting and modifying L-cys through an amide bond. LGG microspheres were constructed using the emulsification gel method, using SOGG and SA to cross-link and load LGG. The LGG microspheres have good biocompatibility. The present invention utilizes the characteristics that the mercapto group of SOGG can auto-oxidize to form a disulfide bond and SA gels with Ca 2+ ions to prepare double network cross-linked microspheres. The microspheres have intestinal adhesion and gastric acid resistance, which can improve the survival rate of LGG in the stomach; the sulfhydryl groups on the microspheres play a role in connecting probiotics and intestinal mucus, increasing the colonization and adhesion of probiotics in the intestines , which helps probiotics play a probiotic role in the intestines. The invention provides a theoretical basis for the application of probiotics in dairy products, beverages and pharmaceutical industries.
经体外模拟胃肠液实验验证,本发明制备的LGG微球提高了LGG在胃酸中的存活率和肠道黏附性,对LGG具有保护作用。It has been verified by in vitro simulated gastrointestinal fluid experiments that the LGG microspheres prepared in the present invention improve the survival rate and intestinal adhesion of LGG in gastric acid, and have a protective effect on LGG.
经体内模拟试验,通过3% DSS诱导构建的结肠炎小鼠模型证明了与游离LGG治疗结肠炎相比,本发明的LGG微球治疗可以显著缓解DSS造成的结肠缩短、小鼠体重减轻、疾病活动指数升高和脾系数变大,并减少结肠炎性细胞浸润,说明LGG微球可以有效缓解结肠炎且治疗效果较好。Through in vivo simulation tests, the colitis mouse model induced by 3% DSS proved that compared with the treatment of colitis with free LGG, the LGG microsphere treatment of the present invention can significantly alleviate the colon shortening, mouse weight loss, and disease caused by DSS. The activity index increased, the spleen coefficient became larger, and the infiltration of colonic inflammatory cells was reduced, indicating that LGG microspheres can effectively relieve colitis and have good therapeutic effects.
附图说明Description of drawings
构成本发明的一部分的说明书附图用来提供对本发明的进一步理解,本发明的示意性实施例及其说明用于解释本发明,并不构成对本发明的不当限定。The description and drawings that constitute a part of the present invention are used to provide a further understanding of the present invention. The illustrative embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute an improper limitation of the present invention.
图1为本发明实施例1制备的LGG微球的形成机理及发挥作用的原理图;Figure 1 is a schematic diagram of the formation mechanism and function of LGG microspheres prepared in Example 1 of the present invention;
图2为次氯酸钠用量对GG的影响图,其中a为NaClO用量对GG氧化度的影响;b为GG和OGG的透光率;Figure 2 is a graph showing the effect of the dosage of sodium hypochlorite on GG, where a is the effect of the dosage of NaClO on the oxidation degree of GG; b is the transmittance of GG and OGG;
图3为SOGG表征的红外谱图;其中a为GG、OGG和OGG酸化后产物的红外谱图;b为GG、OGG与SOGG的红外谱图;Figure 3 shows the infrared spectrum of SOGG characterization; a is the infrared spectrum of the acidified products of GG, OGG and OGG; b is the infrared spectrum of GG, OGG and SOGG;
图4为GG、OGG、SOGG和L-cys的1HNMR图;Figure 4 shows the 1 HNMR images of GG, OGG, SOGG and L-cys;
图5为巯基接枝率条件筛选图;其中,a为EDC/NHS对巯基含量的影响;b为不同反应pH对巯基含量的影响;c为不同投料比对巯基含量的影响;Figure 5 is a condition screening chart for thiol grafting rate; where a is the effect of EDC/NHS on thiol content; b is the effect of different reaction pH on thiol content; c is the effect of different feeding ratios on thiol content;
图6为LGG微球的制备条件筛选图;其中,a为SOGG浓度对包埋率的影响;b为SA:CaCO3的比例对包埋率的影响;c为水油体积比对包埋率的影响;d为冰醋酸的用量对包埋率的影响;Figure 6 is a screening diagram of the preparation conditions of LGG microspheres; where a is the effect of SOGG concentration on the embedding rate; b is the effect of the ratio of SA:CaCO 3 on the embedding rate; c is the water-oil volume ratio on the embedding rate The influence of; d is the influence of the dosage of glacial acetic acid on the embedding rate;
图7为LGG微球外观形态图;其中,a为冻干后的LGG微球,b为普通光学显微镜下微球的形态图;c、d为不同放大比例下LGG微球的扫描电子显微镜图;Figure 7 shows the appearance and morphology of LGG microspheres; a is the freeze-dried LGG microsphere, b is the morphology of the microspheres under an ordinary optical microscope; c and d are scanning electron microscope images of LGG microspheres under different magnification ratios. ;
图8为LGG微球对模拟胃肠液的耐受性图;其中,a为游离LGG对模拟胃肠液的耐受性;b为LGG微球对模拟胃肠液的耐受性;Figure 8 is a graph showing the tolerance of LGG microspheres to simulated gastrointestinal fluid; where a is the tolerance of free LGG to simulated gastrointestinal fluid; b is the tolerance of LGG microspheres to simulated gastrointestinal fluid;
图9为LGG微球在模拟连续胃肠的耐受性;Figure 9 shows the tolerance of LGG microspheres in simulated continuous gastrointestinal tract;
图10为LGG与膜黏附性测试结果;其中,a为四种不同多糖的薄膜;b为LGG与不同薄膜的黏附性;Figure 10 shows the test results of adhesion between LGG and film; where a is the film of four different polysaccharides; b is the adhesion between LGG and different films;
图11为LGG微球对小鼠体重的影响;Figure 11 shows the effect of LGG microspheres on mouse body weight;
图12为小鼠心、肝、脾、肺、肾的经H&E染色后的病理学图像Figure 12 shows pathological images of mouse heart, liver, spleen, lung, and kidney after H&E staining.
图13为实验过程中小鼠体重变化情况;Figure 13 shows the changes in mouse body weight during the experiment;
图14为实验过程中小鼠的DAI评分;Figure 14 shows the DAI score of mice during the experiment;
图15为各组小鼠(a)结肠长度;(b)HE染色及组织学评分(200×);注a:与空白组比较,###P<0.0001;注b:与模型组比较,***P<0.005,****P<0.0001;Figure 15 shows (a) colon length of mice in each group; (b) HE staining and histological score (200×); Note a: compared with the blank group, ###P<0.0001; Note b: compared with the model group, ***P<0.005, ****P<0.0001;
图16为小鼠的脾脏系数;注a:与空白组比较,###P<0.0001;注b:与模型组比较,****P<0.0001;Figure 16 shows the spleen coefficient of mice; Note a: compared with the blank group, ###P<0.0001; Note b: compared with the model group, ****P<0.0001;
图17为MPO酶活力;注a:与空白组比较,###P<0.0001;注b:与模型组比较,****P<0.0001;Figure 17 shows the MPO enzyme activity; Note a: compared with the blank group, ###P<0.0001; Note b: compared with the model group, ****P<0.0001;
图18为小鼠结肠(a)IL-10、(b)TNF-α和(c)IL-6的免疫组化(200×);注a:与空白组比较,**P<0.05;注b:与模型组比较,#P<0.01,##P<0.05,###P<0.001。Figure 18 shows the immunohistochemistry (200×) of (a) IL-10, (b) TNF-α and (c) IL-6 in mouse colon; Note a: Compared with the blank group, **P<0.05; Note b: Compared with the model group, #P<0.01, ##P<0.05, ###P<0.001.
具体实施方式Detailed ways
鉴于益生菌在胃液中的存活率较低,在肠道内中的黏附性较差的问题,本发明提出了一种巯基化氧化瓜尔豆胶/海藻酸钠微球及其制备方法与应用。In view of the problems of low survival rate of probiotics in gastric juice and poor adhesion in the intestinal tract, the present invention proposes a thiolated oxidized guar gum/sodium alginate microsphere and its preparation method and application.
本发明的一种典型实施方式,提供了一种巯基化氧化瓜尔豆胶/海藻酸钠微球的制备方法,包括如下步骤:A typical embodiment of the present invention provides a method for preparing thiolated oxidized guar gum/sodium alginate microspheres, which includes the following steps:
S1、通过对GG进行TEMPO氧化反应得到OGG,通过酰胺化反应将L-cys接枝到OGG分子链上生成SOGG;S1. OGG is obtained by performing TEMPO oxidation reaction on GG, and L-cys is grafted onto the OGG molecular chain through amidation reaction to generate SOGG;
S2、配置含SOGG、SA和碳酸钙的混合液,向混合液中加入菌悬液并搅匀,得到水相;配置含Span80的液体石蜡溶液,Span80充分溶解,得到油相;将水相缓慢加入油相中,乳化,搅拌形成W/O液滴后,加入冰醋酸继续搅拌,使固化;破乳,静置,离心,除去油相,收集得到微球。S2. Prepare a mixed solution containing SOGG, SA and calcium carbonate, add bacterial suspension to the mixed solution and stir well to obtain a water phase; prepare a liquid paraffin solution containing Span80, fully dissolve Span80 to obtain an oil phase; slowly add the water phase Add to the oil phase, emulsify, stir to form W/O droplets, add glacial acetic acid and continue stirring to solidify; break the emulsification, let stand, centrifuge, remove the oil phase, and collect microspheres.
本发明将SOGG与SA通过离子交联和二硫键交联制备负载益生菌的微球。SOGG中游离的巯基具有黏附性可以解决益生菌在肠道黏附定植的问题。SOGG中巯基自氧化形成二硫键可以交联制备微球。SA与Ca2+螯合形成的离子在胃内不裂解,在肠道碱性环境中形成氢氧化钙裂解,起到了在胃内保护益生菌的作用。然而,单一的SA微球具有较多孔隙,且机械性能差,对益生菌的保护效果不佳。因此,将SA与SOGG复配交联形成双网络水凝胶,从而减小SA水凝胶的多孔结构。同时,GG可被结肠细菌降解起到益生菌结肠靶向释放的效果。肠粘液由许多半胱氨酸的糖蛋白粘蛋白组成,具有丰富的巯基。巯基化聚合物可与益生菌表面蛋白上的半胱氨酸形成二硫键。硫聚物也可以通过巯基或二硫键的交换反应与粘液凝胶层形成二硫键。因此,硫聚物可以作为连接益生菌和粘液的桥梁,实现益生菌与粘液的长时间粘附。本发明将SOGG与SA复配,形成具有离子螯合和二硫键双网络微球,实现对益生菌的保护和肠道黏附定植的作用。In the present invention, SOGG and SA are used to prepare probiotic-loaded microspheres through ionic cross-linking and disulfide bond cross-linking. The free sulfhydryl groups in SOGG are adhesive and can solve the problem of adhesion and colonization of probiotics in the intestine. The sulfhydryl groups in SOGG auto-oxidize to form disulfide bonds, which can be cross-linked to prepare microspheres. The ions formed by the chelation of SA and Ca 2+ do not decompose in the stomach, but form calcium hydroxide in the alkaline intestinal environment and decompose, which plays a role in protecting probiotics in the stomach. However, a single SA microsphere has many pores and poor mechanical properties, and has poor protective effect on probiotics. Therefore, SA and SOGG were compounded and cross-linked to form a double network hydrogel, thereby reducing the porous structure of the SA hydrogel. At the same time, GG can be degraded by colon bacteria to achieve colon-targeted release of probiotics. Intestinal mucus is composed of glycoprotein mucins with many cysteine residues and is rich in sulfhydryl groups. Thiolated polymers can form disulfide bonds with cysteine residues on probiotic surface proteins. Thiopolymers can also form disulfide bonds with the mucus gel layer through exchange reactions of sulfhydryl groups or disulfide bonds. Therefore, sulfopolymers can serve as a bridge between probiotics and mucus, enabling long-term adhesion of probiotics to mucus. The present invention combines SOGG and SA to form microspheres with a double network of ion chelation and disulfide bonds, thereby achieving the effects of protecting probiotics and adhering to intestinal colonization.
该实施方式的一些实施例中,所述菌为鼠李糖乳杆菌CICC 6141(Lactobacillusrhamnosus),购自中国工业微生物菌种保藏管理中心。In some examples of this embodiment, the bacterium is Lactobacillus rhamnosus CICC 6141 (Lactobacillus rhamnosus), purchased from the China Industrial Microbial Culture Collection Center.
该实施方式的一些实施例中,所述TEMPO氧化反应包括如下步骤:In some examples of this embodiment, the TEMPO oxidation reaction includes the following steps:
将GG溶解在去离子水中,加入NaBr和TEMPO,溶解后将溶液置于冰水浴中;调节pH为10-10.5,向溶液中滴加NaClO溶液,10min内滴完,控制pH为10-10.5,直到NaClO全部耗尽、反应的pH不再变化为止,终止氧化反应;醇沉,沉淀物离心后洗涤;分离后的沉淀物重新溶解在水中,透析,冷冻干燥,即得OGG。Dissolve GG in deionized water, add NaBr and TEMPO, put the solution in an ice water bath after dissolution; adjust the pH to 10-10.5, add NaClO solution dropwise to the solution, finish dripping within 10 minutes, and control the pH to 10-10.5. The oxidation reaction is terminated until all NaClO is consumed and the pH of the reaction no longer changes; alcohol is precipitated, and the precipitate is centrifuged and washed; the separated precipitate is redissolved in water, dialyzed, and freeze-dried to obtain OGG.
其中,OGG的合成路线如下所示:Among them, the synthesis route of OGG is as follows:
该实施方式的一些实施例中,所述GG的分子量为200-250kDa,且水溶液多为浑浊。GG分子链存在大量的羟基,分子内氢键自交联是GG溶解性差的主要原因。In some examples of this embodiment, the molecular weight of GG is 200-250 kDa, and the aqueous solution is mostly turbid. There are a large number of hydroxyl groups in the GG molecular chain, and intramolecular hydrogen bond self-crosslinking is the main reason for the poor solubility of GG.
该实施方式的一些实施例中,GG与去离子水的用量比为0.2-0.8g:190-210mL。In some examples of this embodiment, the dosage ratio of GG to deionized water is 0.2-0.8g:190-210mL.
该实施方式的一些实施例中,NaBr的加入量为0.25-0.27g/g,GG。In some examples of this embodiment, the amount of NaBr added is 0.25-0.27g/g, GG.
该实施方式的一些实施例中,TEMPO的加入量为18-22mg/g,GG。In some examples of this embodiment, the added amount of TEMPO is 18-22 mg/g, GG.
该实施方式的一些实施例中,所述NaClO溶液中有效氯含量为10%;NaClO的用量为20-25mmol/g,GG。在TEMPO氧化体系中,NaClO作为氧化剂,其用量的多少决定着GG氧化度的高低。TEMPO氧化体系能够将GG的C6位羟基氧化为羧基,在20-25mmol/g,GG的用量下,TEMPO氧化体系可以将GG C6位的羟基氧化度达到90%以上。当NaClO用量再增加时,氧化度基本不变。In some examples of this embodiment, the available chlorine content in the NaClO solution is 10%; the dosage of NaClO is 20-25 mmol/g, GG. In the TEMPO oxidation system, NaClO is used as an oxidant, and its dosage determines the degree of GG oxidation. The TEMPO oxidation system can oxidize the hydroxyl group at the C6 position of GG to a carboxyl group. At a dosage of 20-25mmol/g of GG, the TEMPO oxidation system can oxidize the hydroxyl group at the C6 position of GG to more than 90%. When the amount of NaClO is increased, the degree of oxidation remains basically unchanged.
该实施方式的一些实施例中,所述酰胺化反应包括如下步骤:In some examples of this embodiment, the amidation reaction includes the following steps:
配置质量分数为0.15-0.25%的OGG水溶液,加入EDC活化羧基,15-25min之后加入NHS固定羧基,室温下避光搅拌反应30-50min;将L-cys加入反应液中,调节pH,避光环境下室温连续搅拌24h;反应结束后,透析以除去未反应的试剂;将透析后的液体冷冻干燥,得SOGG。Prepare an OGG aqueous solution with a mass fraction of 0.15-0.25%, add EDC to activate the carboxyl group, add NHS to fix the carboxyl group after 15-25 minutes, stir the reaction at room temperature in the dark for 30-50 minutes; add L-cys to the reaction solution, adjust the pH, and avoid light Stir continuously at room temperature for 24 hours; after the reaction is completed, dialyze to remove unreacted reagents; freeze-dry the dialyzed liquid to obtain SOGG.
其中,SOGG的合成路线如下所示:Among them, the synthesis route of SOGG is as follows:
该实施方式的一些实施例中,所述pH为5.0-6.0。反应pH影响SOGG中的巯基含量。当反应pH增加时,SOGG中的巯基含量出现先增加后降低的情况。当pH=5.5时,巯基含量达到最高。In some examples of this embodiment, the pH is 5.0-6.0. The reaction pH affects the thiol content in SOGG. When the reaction pH increases, the thiol content in SOGG first increases and then decreases. When pH=5.5, the sulfhydryl content reaches the highest level.
该实施方式的一些实施例中,EDC:NHS=4-5:1质量比。EDC/NHS的比例也影响SOGG中的巯基含量。EDC起活化羧基的作用,NHS有固定羧基的作用。当EDC/NHS=5:1,此时巯基含量达到最高。这可能是因为NHS固定羧基与活化后的羧基相结合,跟L-cys有竞争关系。In some examples of this implementation, EDC:NHS=4-5:1 mass ratio. The ratio of EDC/NHS also affects the sulfhydryl content in SOGG. EDC plays the role of activating carboxyl groups, and NHS plays the role of fixing carboxyl groups. When EDC/NHS=5:1, the sulfhydryl content reaches the highest level. This may be because the NHS fixed carboxyl group combines with the activated carboxyl group and competes with L-cys.
该实施方式的一些实施例中,OGG与L-cys的质量比为1:5-10。OGG/L-cys的质量比也影响SOGG中的巯基含量。随着L-cys的投入量增多,SOGG中的巯基含量先增加后减小。当投料比为1:7时,游离巯基含量最高。In some examples of this implementation, the mass ratio of OGG to L-cys is 1:5-10. The mass ratio of OGG/L-cys also affects the sulfhydryl content in SOGG. As the input amount of L-cys increases, the thiol content in SOGG first increases and then decreases. When the feed ratio is 1:7, the free thiol content is the highest.
该实施方式的一些实施例中,OGG与EDC之间的用量比为1:5。In some examples of this implementation, the dosage ratio between OGG and EDC is 1:5.
该实施方式的一些实施例中,所述菌悬液的浓度为2×109cfu/mL;菌悬液与所述混合液的体积比为1:5。In some examples of this embodiment, the concentration of the bacterial suspension is 2×10 9 cfu/mL; the volume ratio of the bacterial suspension and the mixed liquid is 1:5.
该实施方式的一些实施例中,所述液体石蜡溶液中,Span80的体积分数为1.5%-2.5%,进一步优选为2%。In some examples of this embodiment, the volume fraction of Span80 in the liquid paraffin solution is 1.5%-2.5%, more preferably 2%.
该实施方式的一些实施例中,所述水相中,SOGG的浓度为0.25%-0.75%,质量百分数。SOGG的浓度影响微球中益生菌的包埋率。微球的包埋率随SOGG的浓度增加,呈先增加后减小的趋势。当SOGG浓度为0.5%时,微球的包埋率最大。In some examples of this embodiment, the concentration of SOGG in the aqueous phase is 0.25%-0.75%, mass percentage. The concentration of SOGG affects the encapsulation rate of probiotic bacteria in microspheres. The embedding rate of microspheres increases first and then decreases as the concentration of SOGG increases. When the SOGG concentration is 0.5%, the embedding rate of microspheres is maximum.
该实施方式的一些实施例中,所述水相中,SA与CaCO3的质量比为1:3-5。微球的包封效果与SA与CaCO3的质量比密切相关。因此SA/CaCO3质量比的高低都会影响微球的包埋效果。在1:4的比例下,微球的包埋效果较好。In some examples of this embodiment, the mass ratio of SA to CaCO 3 in the aqueous phase is 1:3-5. The encapsulation effect of microspheres is closely related to the mass ratio of SA to CaCO3 . Therefore, the mass ratio of SA/CaCO 3 will affect the embedding effect of microspheres. At the ratio of 1:4, the embedding effect of microspheres is better.
该实施方式的一些实施例中,水相与油相的体积比为1:2-4。在微球的制备过程中,乳化起到关键作用。水油体积比可以影响微球的粒径进而影响微球质量。当油相体积逐渐增多时,微球的包埋率呈现先上升后下降的趋势。在1:3的体积比下,制得的微球质量好。In some examples of this embodiment, the volume ratio of the water phase to the oil phase is 1:2-4. In the preparation process of microspheres, emulsification plays a key role. The water-oil volume ratio can affect the particle size of microspheres and thus the quality of microspheres. When the volume of the oil phase gradually increases, the embedding rate of microspheres first increases and then decreases. At a volume ratio of 1:3, the quality of the microspheres produced was good.
该实施方式的一些实施例中,所述冰醋酸的加入量为0.25-0.35mL,进一步优选的0.3mL。冰醋酸与碳酸钙反应释放Ca2+,对SA成胶起关键作用。冰醋酸使用过少,不利于SA成胶,不易制备微球;使用过多pH酸性太强,会造成益生菌的死亡。在0.25-0.35mL的用量下,所得微球的质量以及包埋后活菌数量均较好。In some examples of this embodiment, the added amount of glacial acetic acid is 0.25-0.35 mL, and more preferably 0.3 mL. Glacial acetic acid reacts with calcium carbonate to release Ca 2+ , which plays a key role in SA gel formation. If too little glacial acetic acid is used, it is not conducive to SA gel formation and it is difficult to prepare microspheres; if too much glacial acetic acid is used, the pH will be too acidic, which will cause the death of probiotics. At the dosage of 0.25-0.35mL, the quality of the microspheres obtained and the number of viable bacteria after embedding were both good.
该实施方式的一些实施例中,综合考虑SOGG浓度、SA/CaCO3质量比、水油体积比和冰醋酸用量对LGG微球包埋率影响,通过正交实验得到LGG微球的最佳制备工艺条件为:水相中,SOGG的浓度为0.5%,SA与碳酸钙的质量比为1:3,水相与油相的体积比为1:3,冰醋酸的加入量为0.3mL。In some examples of this embodiment, the optimal preparation of LGG microspheres was obtained through orthogonal experiments by comprehensively considering the effects of SOGG concentration, SA/CaCO 3 mass ratio, water-to-oil volume ratio, and glacial acetic acid dosage on the encapsulation rate of LGG microspheres. The process conditions are: in the water phase, the concentration of SOGG is 0.5%, the mass ratio of SA to calcium carbonate is 1:3, the volume ratio of the water phase to the oil phase is 1:3, and the addition amount of glacial acetic acid is 0.3 mL.
本发明的另一种典型实施方式,提供了一种巯基化氧化瓜尔豆胶/海藻酸钠微球,所述巯基化氧化瓜尔豆胶/海藻酸钠微球由上述制备方法制得。Another typical embodiment of the present invention provides a thiolated oxidized guar gum/sodium alginate microsphere, which is prepared by the above preparation method.
该实施方式的一些实施例中,所述巯基化氧化瓜尔豆胶/海藻酸钠微球具有表面光滑的规则球形结构,平均粒径为260-350μm。In some examples of this embodiment, the thiolated oxidized guar gum/sodium alginate microspheres have a regular spherical structure with a smooth surface and an average particle size of 260-350 μm.
本发明的另一种典型实施方式,提供了上述的一种巯基化氧化瓜尔豆胶/海藻酸钠微球在生物医用材料领域中的应用。Another typical embodiment of the present invention provides the application of the above-mentioned thiolated oxidized guar gum/sodium alginate microspheres in the field of biomedical materials.
该实施方式的一些实施例中,所述应用为制备治疗结肠炎相关药物中的应用。In some examples of this embodiment, the application is in the preparation of medicaments related to the treatment of colitis.
为了使得本领域技术人员能够更加清楚地了解本发明的技术方案,以下将结合具体的实施例详细说明本发明的技术方案。In order to enable those skilled in the art to understand the technical solution of the present invention more clearly, the technical solution of the present invention will be described in detail below with reference to specific embodiments.
实施例1Example 1
1、实验材料1. Experimental materials
1.1主要符号1.1 Main symbols
实验中所用符号如表1所示。The symbols used in the experiments are shown in Table 1.
表1主要符号表Table 1 Main symbol table
1.2主要试剂1.2 Main reagents
实验中所用主要材料与试剂如表2所示The main materials and reagents used in the experiment are shown in Table 2
表2主要材料与试剂Table 2 Main materials and reagents
菌种:鼠李糖乳杆菌CICC 6141(Lactobacillus rhamnosus)在中国工业微生物菌种保藏管理中心购买。Strain: Lactobacillus rhamnosus CICC 6141 (Lactobacillus rhamnosus) was purchased from the China Industrial Microbial Culture Collection Center.
细胞:巨噬细胞RAW264.7由本实验室培养。Cells: Macrophages RAW264.7 were cultured in our laboratory.
1.3主要仪器1.3 Main instruments
实验中所用主要仪器如表3所示The main instruments used in the experiment are shown in Table 3
表3主要仪器Table 3 Main instruments
2、试验方法2. Test method
2.1OGG的合成2.1Synthesis of OGG
(1)称取0.5g GG在200mL的去离子水中搅拌至完全溶解,加入0.13g NaBr(0.26g/g,以GG计),10mg TEMPO(20mg/g,以GG计),持续搅拌至TEMPO和NaBr完全溶解。(1) Weigh 0.5g GG and stir in 200mL of deionized water until completely dissolved. Add 0.13g NaBr (0.26g/g, calculated as GG), 10mg TEMPO (20mg/g, calculated as GG), and continue stirring until TEMPO and NaBr completely dissolved.
(2)将溶液置于0℃冰水浴中,调节pH至10.3(±0.02),逐滴加入NaClO溶液,10min内滴完,启动TEMPO介导的氧化过程,用0.5M NaOH维持反应的pH在10.3(±0.02)。每隔10min记录NaOH溶液消耗的用量,直至反应的pH不再变化为止。(2) Place the solution in an ice water bath at 0°C, adjust the pH to 10.3 (±0.02), add NaClO solution drop by drop, finish dropping within 10 minutes, start the TEMPO-mediated oxidation process, and use 0.5M NaOH to maintain the pH of the reaction at 10.3(±0.02). Record the amount of NaOH solution consumed every 10 minutes until the pH of the reaction no longer changes.
(3)加入20mL 95%乙醇,调节溶液的pH至7,终止反应。(3) Add 20 mL of 95% ethanol, adjust the pH of the solution to 7, and terminate the reaction.
(4)加入3倍体积乙醇析出OGG,沉淀物用75%的乙醇溶液洗涤3次,重新在水中溶解,将溶液转移至透析袋于超纯水中透析72h,除去未反应的试剂。(4) Add 3 times the volume of ethanol to precipitate OGG. The precipitate is washed three times with 75% ethanol solution and redissolved in water. The solution is transferred to a dialysis bag and dialyzed in ultrapure water for 72 hours to remove unreacted reagents.
(5)将透析后的OGG置于-80℃冰箱中冷冻过夜,后冷冻干燥48h得到棉絮状固体。(5) The dialyzed OGG was frozen in a -80°C refrigerator overnight, and then freeze-dried for 48 hours to obtain a cotton-like solid.
(6)OGG的酸化(HOGG):将1g/L OGG分散在99%的乙酸溶液中,加入10% HCl(37%,v/v),混合20min,1000g离心20min,干燥,除去多余的酸。将OGG上的羧酸盐转化为酸性形式(羧酸),用于后续表征。(6) Acidification of OGG (HOGG): Disperse 1g/L OGG in 99% acetic acid solution, add 10% HCl (37%, v/v), mix for 20min, centrifuge at 1000g for 20min, dry, and remove excess acid . The carboxylate on OGG was converted to the acidic form (carboxylic acid) for subsequent characterization.
2.2SOGG的合成2.2Synthesis of SOGG
(1)称取OGG 0.094g于蒸馏水中搅拌过夜,制成0.2%溶液,加入EDC活化羧基,20min之后加入NHS固定羧基,室温下避光搅拌反应40min。(1) Weigh 0.094g of OGG and stir in distilled water overnight to make a 0.2% solution. Add EDC to activate the carboxyl group. After 20 minutes, add NHS to fix the carboxyl group. Stir and react for 40 minutes at room temperature in the dark.
(2)加入与OGG/L-cys不同质量比(1:1、1:3、1:5、1:7和1:10)的L-cys于反应液中,调节反应pH(4.0、4.5、5.0、5.5和6.0),避光,室温连续搅拌24h。(2) Add L-cys with different mass ratios to OGG/L-cys (1:1, 1:3, 1:5, 1:7 and 1:10) into the reaction solution, and adjust the reaction pH (4.0, 4.5 , 5.0, 5.5 and 6.0), protected from light, and stirred continuously at room temperature for 24 hours.
(3)反应结束后,用拦截分子量为7500的透析袋透析3d以除去未反应的试剂。使用的透析介质:第1d,pH=5的去离子水;第2d,含有1% NaCl的pH=5的去离子水;第3d,pH=5的去离子水。每隔12h换一次水,除去未反应的试剂。(3) After the reaction, dialyze for 3 days using a dialysis bag with a molecular weight intercept of 7500 to remove unreacted reagents. The dialysis medium used was: deionized water with pH=5 on day 1; deionized water with pH=5 containing 1% NaCl on day 2; deionized water with pH=5 on day 3. Change the water every 12 hours and remove unreacted reagents.
(4)将透析后的液体转移置于-80℃冰箱中冷冻过夜,后冷冻干燥48h得到棉絮状固体。(4) Transfer the dialyzed liquid and freeze it in a -80°C refrigerator overnight, and then freeze-dry it for 48 hours to obtain a cotton-like solid.
2.3LGG微球的制备2.3 Preparation of LGG microspheres
2.3.1制备LGG菌悬浮液2.3.1 Preparation of LGG bacterial suspension
在超净工作台中以2%的接种量将LGG菌种接种到10mL MRS肉汤培养基中,在37℃恒温培养箱中培养24h。然后将活化好的LGG菌种以2%的接种量进行传代。以2%的接种量接种到体积为200mL的肉汤培养基中,在37℃恒温培养箱中培养14h。以此步骤再进行一次传代。将培养好的菌液4000rpm,10min离心,除去上清。用灭菌的0.85% NaCl溶液洗涤菌泥,重复三次,直至上清变为无色。最后用0.85%生理盐水将菌泥重悬,配制菌液浓度为2×109cfu/mL置于4℃冰箱保存备用。The LGG strain was inoculated into 10 mL MRS broth culture medium at an inoculum volume of 2% in a clean workbench, and cultured in a 37°C constant temperature incubator for 24 h. The activated LGG strain was then passaged at an inoculum volume of 2%. Inoculate 2% of the inoculum into a 200 mL broth medium and culture it in a 37°C constant-temperature incubator for 14 h. Perform this step again for passage. Centrifuge the cultured bacterial solution at 4000 rpm for 10 minutes and remove the supernatant. Wash the bacterial slurry with sterile 0.85% NaCl solution three times until the supernatant becomes colorless. Finally, resuspend the bacterial sludge with 0.85% physiological saline, and prepare the bacterial liquid with a concentration of 2×10 9 cfu/mL and store it in a 4°C refrigerator for later use.
2.3.2LGG微球的制备2.3.2 Preparation of LGG microspheres
分别称取SOGG和SA溶于去离子水中,搅拌过夜充分溶解。Weigh SOGG and SA respectively, dissolve them in deionized water, and stir overnight to fully dissolve them.
水相:配制含SOGG、SA和CaCO3的混合液,充分搅拌使其混合均匀;将2.3.1中菌悬液与混合液按照体积比1:5涡旋搅拌混合均匀。Water phase: Prepare a mixed solution containing SOGG, SA and CaCO 3 , stir thoroughly to mix evenly; vortex and mix the bacterial suspension and the mixed solution in 2.3.1 according to a volume ratio of 1:5.
油相:含体积分数2% Span80的液体石蜡,在45℃搅拌使Span80充分溶解。Oil phase: liquid paraffin containing 2% Span80 by volume, stir at 45°C to fully dissolve Span80.
将5mL水相缓慢加入20mL油相中,用磁力搅拌器粗乳化,再用剪切均质机5000rpm细乳化10min,通过机械搅拌形成W/O液滴后,加入200μL冰醋酸继续搅拌40min,使其充分固化;加入4倍体积的灭菌缓冲溶液破乳,静置2h,微球由于重力作用沉淀在烧杯底部,油相则漂浮在水上层。离心(4000rpm,10min),除去油相及表面活性剂,重复三次,收集微球;将收集得到的益生菌微球保存于4℃冰箱中。如图1为LGG微球的形成机理及发挥作用的原理图。Slowly add 5 mL of water phase into 20 mL of oil phase, use a magnetic stirrer to coarsely emulsify, and then use a shear homogenizer at 5000 rpm to finely emulsify for 10 min. After mechanical stirring to form W/O droplets, add 200 μL of glacial acetic acid and continue stirring for 40 min. It is fully solidified; add 4 times the volume of sterilized buffer solution to break the emulsification, and let it stand for 2 hours. The microspheres will settle at the bottom of the beaker due to gravity, and the oil phase will float on the water layer. Centrifuge (4000 rpm, 10 min) to remove the oil phase and surfactant, repeat three times, and collect the microspheres; store the collected probiotic microspheres in a 4°C refrigerator. Figure 1 is a schematic diagram of the formation mechanism and function of LGG microspheres.
3、优化与表征3. Optimization and characterization
3.1OGG的表征3.1 Characterization of OGG
3.1.1次氯酸钠用量对OGG氧化度的影响3.1.1 Effect of sodium hypochlorite dosage on OGG oxidation degree
在TEMPO氧化体系中,NaClO作为氧化剂,其用量的多少决定着GG氧化度的高低。在OGG的合成过程中,向0.25%GG多糖溶液中加入pH=10.3的NaClO溶液,多糖溶液的pH开始降低,加入0.5MNaOH溶液,保持GG多糖溶液的pH为10.3。当溶液pH不再降低时,继续加入NaClO溶液,持续用0.5M NaOH溶液中和,此过程一直循环直至再滴加NaClO溶液,多糖溶液pH基本不变。记录NaClO溶液的消耗量与氧化度OD之间的变化关系。In the TEMPO oxidation system, NaClO is used as an oxidant, and its dosage determines the degree of GG oxidation. During the synthesis of OGG, a NaClO solution with pH = 10.3 was added to the 0.25% GG polysaccharide solution. The pH of the polysaccharide solution began to decrease. A 0.5M NaOH solution was added to maintain the pH of the GG polysaccharide solution at 10.3. When the pH of the solution no longer decreases, continue to add NaClO solution, and continue to neutralize with 0.5M NaOH solution. This process continues until NaClO solution is added dropwise, and the pH of the polysaccharide solution remains basically unchanged. Record the relationship between the consumption of NaClO solution and the oxidation degree OD.
3.1.2FTIR3.1.2FTIR
GG、OGG冻干后的样品与干燥的溴化钾质量比为1:100,用玛瑙研钵将样品与溴化钾充分混匀,压片机压片,傅立叶红外光谱仪分别对GG和OGG进行红外扫描。The mass ratio of the freeze-dried samples of GG and OGG to dried potassium bromide is 1:100. Use an agate mortar to mix the sample and potassium bromide thoroughly, press the tablets with a tablet press, and measure GG and OGG with a Fourier transform infrared spectrometer respectively. Infrared scanning.
3.2SOGG的表征3.2 Characterization of SOGG
3.2.1FTIR3.2.1FTIR
同3.1.2中实验方法。Same as the experimental method in 3.1.2.
3.2.2 1HNMR3.2.2 1 HNMR
分别取10mg GG、SOGG充分溶解于1mL D2O中,利用1HNMR在BrukerAM500光谱仪上解析其化学结构。Take 10 mg of GG and SOGG respectively and fully dissolve them in 1 mL of D 2 O, and use 1 H NMR to analyze their chemical structures on a Bruker AM500 spectrometer.
3.2.3Ellman法测巯基含量3.2.3 Determination of sulfhydryl content by Ellman method
Ellman试剂定量检测自由巯基的基本原理如下所示:The basic principle of Ellman's reagent for quantitative detection of free sulfhydryl groups is as follows:
DTNB在412nm处没有紫外光谱吸收,当与含有巯基的样品交联发生反应后,生成2-硝基-5-巯基苯甲酸(TNB2-),TNB2-在412nm处有很强的紫外吸收,该反应有较高的特异性。本实验通过用紫外分光光度法测定标准品L-cys样品的标准曲线,再通过标准曲线测定SOGG中的巯基含量。DTNB has no UV spectrum absorption at 412nm. When cross-linked with samples containing thiol groups, it generates 2-nitro-5-mercaptobenzoic acid (TNB 2- ). TNB 2- has strong UV absorption at 412nm. , this reaction has high specificity. In this experiment, UV spectrophotometry was used to determine the standard curve of the standard L-cys sample, and then the sulfhydryl content in SOGG was determined through the standard curve.
3.3LGG微球制备工艺优化3.3 Optimization of preparation process of LGG microspheres
通过单因素试验测定不同SOGG质量分数(0、0.5%、1.0%、1.5%、2.0%);SA:CaCO3质量比(1:1、1:2、1:3、1:4、1:5);水油体积比(1:1、1:2、1:3、1:4、1:5);冰醋酸的用量(0.2mL、0.3mL、0.4mL、0.5mL、0.6mL)对微球包埋效果的影响。以益生菌的包埋率为指标,采用正交试验L9(34)设计,研究4个因素对微球包埋率的影响。SOGG-SA微球配方L9(34)正交试验设计如表4所示。Different SOGG mass fractions (0, 0.5%, 1.0%, 1.5%, 2.0%) were determined through single factor experiments; SA:CaCO 3 mass ratios (1:1, 1:2, 1:3, 1:4, 1: 5); water to oil volume ratio (1:1, 1:2, 1:3, 1:4, 1:5); dosage of glacial acetic acid (0.2mL, 0.3mL, 0.4mL, 0.5mL, 0.6mL). Effect of microsphere embedding effect. Taking the encapsulation rate of probiotics as an indicator, an orthogonal experiment L 9 (3 4 ) design was used to study the influence of four factors on the entrapment rate of microspheres. The orthogonal experimental design of SOGG-SA microsphere formula L 9 (3 4 ) is shown in Table 4.
表4正交实验因素水平表Table 4 Orthogonal Experiment Factor Level Table
3.3.1微球包埋率的测定3.3.1 Determination of microsphere embedding rate
将0.5g微球加入到9mL裂解溶液中进行微球裂解,在摇床中37℃、230r/min上下震荡1h,取样,平板计数法计数。最初添加的活菌数量采用同样方法计数。Add 0.5 g of microspheres to 9 mL of lysis solution for microsphere lysis, shake up and down in a shaker at 37°C and 230 r/min for 1 hour, take samples, and count by plate counting. The number of viable bacteria added initially was counted using the same method.
益生菌包埋率可表示为:包埋率(%)=(m1/m0)*100%The encapsulation rate of probiotics can be expressed as: entrapment rate (%) = (m 1 /m 0 )*100%
式中:m0,起始添加的LGG活菌数,cfu/mL;m1,微球中包埋的LGG活菌数,cfu/mL。In the formula: m 0 , the number of viable LGG bacteria initially added, cfu/mL; m 1 , the number of viable LGG bacteria embedded in the microspheres, cfu/mL.
3.3.2微球外观形态及粒径表征3.3.2 Characterization of appearance, morphology and particle size of microspheres
将微球分散在水中,用荧光倒置显微镜观察,测量微球的粒径,计数100个,取平均值。再通过扫描电子显微镜观察冷冻干燥后载菌微球的微观结构。Disperse the microspheres in water, observe with a fluorescent inverted microscope, measure the particle size of the microspheres, count 100, and take the average value. The microstructure of the freeze-dried bacteria-loaded microspheres was then observed using a scanning electron microscope.
3.3.3LGG微球对模拟胃肠液的耐受性3.3.3 Tolerance of LGG microspheres to simulated gastrointestinal fluid
人工模拟胃液(SGF)的制备:1g胃蛋白酶加入100mL去离子水,加水置于37℃水浴锅中搅拌均匀,用4M的盐酸将pH调节至1.2,用0.2μm的无菌微孔滤膜除菌,现配现用。Preparation of artificial simulated gastric juice (SGF): add 1g pepsin to 100mL deionized water, add water and place in a 37°C water bath and stir evenly, adjust the pH to 1.2 with 4M hydrochloric acid, and remove with a 0.2μm sterile microporous filter membrane Bacteria, ready for use.
人工模拟肠液(SIF)的制备:1g胰蛋白酶加入100mL去离子水,再加入0.65g磷酸二氢钾,用氢氧化钠溶液调节pH至7.4,将上述溶液搅拌均匀,再用0.2μm无菌微孔滤膜过滤备用。Preparation of artificial simulated intestinal fluid (SIF): add 1g trypsin to 100mL deionized water, then add 0.65g potassium dihydrogen phosphate, adjust the pH to 7.4 with sodium hydroxide solution, stir the above solution evenly, and then use 0.2μm sterile microfiber hole filter membrane for filtration.
收集对数生长期的LGG离心,生理盐水洗涤重悬,调节终浓度约为2×109cfu/mL。Collect LGG in the logarithmic growth phase and centrifuge, wash and resuspend with physiological saline, and adjust the final concentration to approximately 2×10 9 cfu/mL.
对模拟胃液的耐受:分别取游离的LGG菌悬液、LGG微球样品到37℃装有10mL模拟胃液试管中,80r/min处理120min。益生菌微球中加入囊解液,在37℃、230r/min裂解1h,益生菌完全释放。通过平板计数法进行活菌计数,培养48h后计数,重复3次取平均值。Tolerance to simulated gastric juice: Take free LGG bacterial suspension and LGG microsphere samples into 10mL simulated gastric juice test tubes at 37°C, and process at 80r/min for 120min. Add the encapsulation solution to the probiotic microspheres and lyse them at 37°C and 230r/min for 1 hour to completely release the probiotics. The viable bacteria were counted by the plate counting method. After 48 h of incubation, the counts were repeated three times and the average value was taken.
对模拟肠液的耐受:分别取游离的LGG菌悬液、LGG微球样品到37℃预热的装有10mL模拟肠液试管中,37℃、80r/min处理4h,其余实验步骤同模拟胃液。Tolerance to simulated intestinal fluid: Take free LGG bacterial suspension and LGG microsphere samples into 10mL simulated intestinal fluid test tubes preheated at 37°C, and process them at 37°C and 80r/min for 4 hours. The remaining experimental steps are the same as those for simulated gastric juice.
对照组:游离LGG加入0.85%生理盐水中。Control group: free LGG was added to 0.85% physiological saline.
对连续胃肠液(GIF)的耐受:分别取游离LGG、LGG微球转移到37℃预热的装有10mL模拟胃液试管中,在37℃摇床80r/min处理120min。离心4000rpm,10min,除去模拟胃液,用生理盐水洗涤3次。分别往游离的LGG菌悬液、LGG微球的试管中加入10mL模拟肠液,37℃、80r/min处理4h。离心,除去模拟肠液,生理盐水洗涤,加入囊解液,裂解1h,平板计数,重复3次取平均值。Tolerance to continuous gastrointestinal fluid (GIF): Free LGG and LGG microspheres were transferred into test tubes containing 10 mL of simulated gastric fluid preheated at 37°C, and treated with a shaker at 80r/min at 37°C for 120 minutes. Centrifuge at 4000 rpm for 10 min to remove simulated gastric juice, and wash three times with physiological saline. Add 10 mL of simulated intestinal fluid to the test tubes of free LGG bacterial suspension and LGG microspheres respectively, and treat at 37°C and 80 r/min for 4 hours. Centrifuge, remove simulated intestinal fluid, wash with physiological saline, add cyst solution, lyse for 1 hour, plate count, repeat 3 times and take the average.
3.3.4黏附性实验3.3.4 Adhesion test
3.3.4.1LGG与膜的黏附性3.3.4.1 Adhesion between LGG and membrane
(1)SA膜、SA+GG膜、SA+OGG膜、SA+SOGG膜的制备(1) Preparation of SA membrane, SA+GG membrane, SA+OGG membrane, SA+SOGG membrane
分别制备膜液30mL为:1.8%SA,1.8%SA+1.0%GG,1.8%SA+1.0%OGG,1.8%SA+1.0%SOGG,室温搅拌6h,充分溶解。随后将1mL甘油添加到膜液中,超声处理20min以去除气泡。将膜液(30mL)分别倒入塑料培养皿(D=9cm)中,并在60℃的烘箱干燥24h。将烘干后的薄膜取出,在50%湿度和25℃的干燥器放置48h后,取出揭膜备用。Prepare 30 mL of film solution respectively: 1.8% SA, 1.8% SA+1.0% GG, 1.8% SA+1.0% OGG, 1.8% SA+1.0% SOGG, stir at room temperature for 6 hours, and fully dissolve. Subsequently, 1 mL of glycerol was added to the membrane liquid and ultrasonicated for 20 min to remove air bubbles. The film liquid (30 mL) was poured into plastic petri dishes (D = 9 cm) and dried in an oven at 60°C for 24 h. Take out the dried film, place it in a desiccator at 50% humidity and 25°C for 48 hours, then take it out and peel it off for later use.
(2)复合薄膜对LGG的黏附作用的测定(2) Determination of the adhesion of composite films to LGG
四种复合薄膜裁剪成1cm2,粘附于载玻片上,并在超净工作台紫外灯下照射30min。将LGG菌悬液(0.2mL,2×108cfu/mL)与薄膜(1cm2)合并,37℃孵育30min,灭菌生理盐水冲洗三次,将冲洗液收集后梯度稀释,未黏附的益生菌细菌数采用平板计数法测定。根据如下黏附率计算公式计算黏附率。The four composite films were cut into 1cm 2 , adhered to the glass slide, and irradiated under ultraviolet light on a clean workbench for 30 minutes. Combine the LGG bacterial suspension (0.2mL, 2×10 8 cfu/mL) and the film (1cm 2 ), incubate at 37°C for 30 minutes, rinse with sterile physiological saline three times, collect the rinse fluid and dilute it gradiently, and remove the unadhered probiotics. The number of bacteria was determined by plate counting method. Calculate the adhesion rate according to the following adhesion rate calculation formula.
黏附率(%)=((A-B)/A)*100%Adhesion rate (%) = ((A-B)/A)*100%
A为总LGG数量,cfu/mL;B为未黏附的LGG数,cfu/mLA is the number of total LGGs, cfu/mL; B is the number of unadhered LGGs, cfu/mL.
3.3.4.2体外模拟益生菌微球与肠道黏附性3.3.4.2 In vitro simulation of probiotic microspheres and intestinal adhesion
根据外翻成囊法,测定复合微粒的黏膜黏附性,实验步骤如下:According to the eversion encapsulation method, the mucosal adhesion of composite particles is measured. The experimental steps are as follows:
雄性C57BL/6J小鼠,取肠道前禁食24h,期间饮水自由。第二天将小鼠处死,开腹,摘取结肠,用生理盐水冲洗肠道并除去肠道内容物,剪取6cm结肠置于PBS缓冲液中保存。将结肠道片段用玻璃棒外翻成囊后,置于含10mg微球的10mL PBS溶液中,在37℃摇床中缓慢振荡30min,取出肠囊,离心,分离出微球,冻干机冷冻干燥48h,称重,根据如下黏膜黏附性计算公式计算黏膜黏附性。Male C57BL/6J mice were fasted for 24 h before intestinal removal, with free access to water during this period. The mice were sacrificed the next day, their abdomen was opened, the colon was removed, the intestine was flushed with physiological saline and the intestinal contents were removed, and 6 cm of the colon was cut and stored in PBS buffer. After everting the colon tract segment into a capsule with a glass rod, place it in 10 mL of PBS solution containing 10 mg of microspheres, shake slowly in a shaker at 37°C for 30 minutes, remove the intestinal capsule, centrifuge, separate the microspheres, and freeze in a freeze dryer Dry for 48 hours, weigh, and calculate mucoadhesion according to the following mucoadhesion calculation formula.
黏膜黏附性(%)=((C-D)/C)*100%Mucoadhesion (%) = ((C-D)/C)*100%
C为初始微球重量,mg;D为未黏附结肠的微球重量,mg。C is the weight of the initial microspheres, mg; D is the weight of the microspheres that have not adhered to the colon, mg.
3.3.5微球的生物相容性3.3.5 Biocompatibility of microspheres
3.3.5.1细胞毒性实验3.3.5.1 Cytotoxicity experiment
采用MTT比色法分别评价SOGG-SA微球对RAW264.7细胞的体外毒性。取200mg空白微球置于1mL培养基中浸提24h,离心收集浸提液。用细胞计数板对RAW264.7细胞进行计数,以5×104个细胞/孔接种至96孔板,于培养箱中孵育24h。将浸提液用培养基分别稀释成不同浓度(200、100、50、25、12.5、6.25mg/mL)。弃去上清,分别换为不同浓度浸提液,每孔100μL,每组6个重复孔培养24h。每孔加入10μL的MTT溶液(5mg/mL),在培养箱中孵育4h后,吸去上清,然后每孔加入150μLDMSO,避光晃匀,使甲臜充分溶解,以未处理的细胞为对照,用酶标仪在570nm波长下检测吸光度,计算细胞存活率。The MTT colorimetric method was used to evaluate the in vitro toxicity of SOGG-SA microspheres to RAW264.7 cells. Take 200 mg of blank microspheres and place them in 1 mL of culture medium for extraction for 24 hours, and centrifuge to collect the extract. RAW264.7 cells were counted using a cell counting plate, seeded into a 96-well plate at 5×10 4 cells/well, and incubated in an incubator for 24 h. The extract liquid was diluted with culture medium to different concentrations (200, 100, 50, 25, 12.5, 6.25 mg/mL). Discard the supernatant and replace with extract solutions of different concentrations, 100 μL per well, and culture 6 replicate wells in each group for 24 hours. Add 10 μL MTT solution (5 mg/mL) to each well, incubate for 4 hours in the incubator, aspirate the supernatant, then add 150 μL DMSO to each well, and shake well in the dark to fully dissolve the formazan. Use untreated cells as a control. , use a microplate reader to detect the absorbance at a wavelength of 570 nm, and calculate the cell survival rate.
存活率(%)=((As-A0)/(Ac-A0))*100%Survival rate (%)=((A s -A 0 )/(A c -A 0 ))*100%
式中As:样品的吸光度值;Ac:未处理细胞组的吸光度;A0:空白孔的吸光度值。In the formula, As : the absorbance value of the sample; Ac : the absorbance of the untreated cell group; A0 : the absorbance value of the blank well.
3.3.5.2溶血实验3.3.5.2 Hemolysis experiment
取大鼠的血液,以1000rpm,10min,4℃离心,除去上清,用PBS反复清洗获得红细胞并稀释至5%(V/V)。将200mg空白微球置于1mL培养基中浸提24h,离心收集浸提液,并将浸提液稀释。将不同稀释后的0.5mL浸提液和0.5mL红细胞混合,置于37℃,100rpm,1h摇床,离心。阳性对照:0.5mL蒸馏水和0.5mL红细胞;空白组:0.5mL PBS缓冲溶液和0.5mL红细胞,用酶标仪测540nm处的吸光度,计算溶血率。Take the blood of rats, centrifuge at 1000 rpm, 10 min, 4°C, remove the supernatant, wash repeatedly with PBS to obtain red blood cells and dilute to 5% (V/V). Place 200 mg of blank microspheres in 1 mL of culture medium and extract for 24 hours, collect the extract by centrifugation, and dilute the extract. Mix 0.5 mL of different diluted extracts and 0.5 mL of red blood cells, place on a shaker at 37°C, 100 rpm, for 1 hour, and centrifuge. Positive control: 0.5mL distilled water and 0.5mL red blood cells; blank group: 0.5mL PBS buffer solution and 0.5mL red blood cells. Use a microplate reader to measure the absorbance at 540nm and calculate the hemolysis rate.
溶血率(%)=((As-An)/(Ap-An))*100Hemolysis rate (%) = ((A s -A n )/(A p -A n ))*100
式中As:样品的吸光度值;An:空白对照组的吸光度;Ap:蒸馏水组的吸光度值。In the formula, As : the absorbance value of the sample; A n : the absorbance value of the blank control group; A p : the absorbance value of the distilled water group.
3.3.5.3体内毒性实验3.3.5.3 In vivo toxicity test
将小鼠在动物房内饲养一周以适应环境。为研究制备的鼠李糖乳杆菌递送体系是否具有系统毒性,将小鼠每日灌胃0.2mL微球,持续7d,并定时检测小鼠体重变化。对照组为等量的生理盐水。实验结束后,将小鼠处死,心肝脾肺肾等器官并用生理盐水冲洗血渍,用4%甲醛固定送样,用光学显微镜进行观察。Mice were kept in the animal room for one week to acclimate. In order to study whether the prepared Lactobacillus rhamnosus delivery system has systemic toxicity, mice were administered 0.2 mL microspheres daily for 7 days, and changes in the mice's body weight were regularly detected. The control group was equal volume of normal saline. After the experiment, the mice were sacrificed, and the blood stains of the heart, liver, spleen, lungs, kidneys and other organs were rinsed with physiological saline, fixed with 4% formaldehyde and sent to the samples for observation with an optical microscope.
4、结果与讨论4. Results and discussion
4.1OGG的表征4.1 Characterization of OGG
4.1.1NaClO用量对GG的影响4.1.1 Effect of NaClO dosage on GG
GG的分子量为220kDa左右,且水溶液多为浑浊。GG分子链存在大量的羟基,分子内氢键自交联是GG溶解性差的主要原因。通过化学改性在GG上引入亲水基团羧基和巯基,从而改善其水溶性。GG水溶液的溶解度可通过透明度进行反映,透明度越高,说明溶解性越好。TEMPO氧化体系能够将GG的C6位羟基氧化为羧基。图2显示GG溶液随着NaClO用量的增加,溶液逐渐由浑浊变澄清;同时,GG的氧化度也逐步增加。通过氧化度计算,TEMPO氧化体系可以将GG的C6位的羟基氧化度达到90%以上。当NaClO用量再增加时,氧化度基本不变。氧化后GG溶液的透光率也不断增加。结果表明羧基的引入能够提高了GG的溶解度,是由于羧基的亲水性加快了水分子对GG浸润的过程。The molecular weight of GG is about 220kDa, and the aqueous solution is mostly turbid. There are a large number of hydroxyl groups in the GG molecular chain, and intramolecular hydrogen bond self-crosslinking is the main reason for the poor solubility of GG. Hydrophilic groups carboxyl and sulfhydryl groups were introduced on GG through chemical modification to improve its water solubility. The solubility of GG aqueous solution can be reflected by the transparency. The higher the transparency, the better the solubility. The TEMPO oxidation system can oxidize the C6 hydroxyl group of GG to a carboxyl group. Figure 2 shows that as the amount of NaClO increases, the GG solution gradually changes from turbid to clear; at the same time, the oxidation degree of GG also gradually increases. Calculated by the degree of oxidation, the TEMPO oxidation system can oxidize the hydroxyl group at the C6 position of GG to more than 90%. When the amount of NaClO is increased, the degree of oxidation remains basically unchanged. The light transmittance of the GG solution also continued to increase after oxidation. The results show that the introduction of carboxyl groups can improve the solubility of GG, because the hydrophilicity of the carboxyl groups accelerates the infiltration process of water molecules into GG.
4.1.2FTIR4.1.2FTIR
由图3a的红外光谱图分析可知,GG、OGG和OGG酸化后产物的主要吸收峰相似,说明GG、OGG和HOGG的主体结构一致,TEMPO氧化体系没有破坏主要结构。GG氧化后羧酸基团中的C=O吸收峰主要出现在1614cm-1,可归因于不对称羧酸盐(COO-)基团和对称COO-的C=O伸缩振动引起的。将OGG酸化后C=O峰移至1734cm-1,说明有-COOH生成,-COOH基团成功引入GG大分子结构上,OGG制备成功。From the infrared spectrum analysis in Figure 3a, it can be seen that the main absorption peaks of the acidified products of GG, OGG and OGG are similar, indicating that the main structures of GG, OGG and HOGG are consistent, and the TEMPO oxidation system does not destroy the main structure. The C=O absorption peak in the carboxylic acid group after GG oxidation mainly appears at 1614 cm -1 , which can be attributed to the C=O stretching vibration of the asymmetric carboxylate (COO-) group and the symmetric COO-. After acidifying OGG, the C=O peak moved to 1734cm -1 , indicating that -COOH was generated, the -COOH group was successfully introduced into the GG macromolecular structure, and OGG was successfully prepared.
4.2SOGG的表征4.2 Characterization of SOGG
4.2.1FTIR4.2.1FTIR
SOGG是通过L-半胱氨酸盐酸盐的胺基与OGG的羧酸盐基团之间形成酰胺键而成的。由图3b观察SOGG在2696cm-1处出现-SH峰,1654cm-1和1541cm-1处出现酰胺峰,分别是酰胺基团的C=O键和-N-H键产生。证明酰胺反应发生,接枝成功;在1608cm-1有羧基峰存在,说明SOGG中羧基与巯基共存。SOGG is formed through the formation of an amide bond between the amine group of L-cysteine hydrochloride and the carboxylate group of OGG. From Figure 3b, it is observed that SOGG has a -SH peak at 2696cm -1 , and amide peaks at 1654cm -1 and 1541cm -1 , which are generated by the C=O bond and -NH bond of the amide group respectively. It proves that the amide reaction occurred and the grafting was successful; there is a carboxyl peak at 1608cm -1 , indicating that carboxyl and sulfhydryl groups coexist in SOGG.
4.2.2 1HNMR4.2.2 1 HNMR
如图4所示,与天然GG和OGG的光谱相比,SOGG的谱图在3.34ppm和2.85ppm处出现明显的特征峰,3.35ppm峰是半胱氨酸衍生物中的-COCH3-部分,2.85ppm与-CH2-SH亚甲基质子的吸收位点相近,这结果表明巯基单元已成功接枝到GG的糖链上,证实了SOGG的成功合成。As shown in Figure 4, compared with the spectra of natural GG and OGG, the spectrum of SOGG has obvious characteristic peaks at 3.34ppm and 2.85ppm. The 3.35ppm peak is the -COCH 3 - moiety in cysteine derivatives. , 2.85ppm is close to the absorption site of -CH 2 -SH methylene proton. This result shows that the thiol unit has been successfully grafted to the sugar chain of GG, confirming the successful synthesis of SOGG.
4.2.3Ellman法测巯基含量4.2.3 Determination of sulfhydryl content by Ellman method
为了准确测定SOGG的巯基接枝程度,首先通过Ellman法确定游离巯基的标准曲线。游离巯基的线性回归方程为:y=12.857x-0.0071,R2=0.9993,吸光度与巯基浓度之间线性关系良好。游离的巯基起的黏附作用,二硫键是微球制备过程中的交联作用。In order to accurately determine the degree of thiol grafting of SOGG, the standard curve of free thiol groups was first determined by the Ellman method. The linear regression equation of free thiol groups is: y=12.857x-0.0071, R 2 =0.9993, and the linear relationship between absorbance and thiol concentration is good. Free sulfhydryl groups play an adhesion role, and disulfide bonds serve as cross-linking effects during the preparation of microspheres.
开始时通过酰胺化反应后的巯基含量为47.67μmol/g,巯基基团含量相对较低,这可能是OGG的分子链较长,分子运动性较低,L-cys不易连接至OGG主链上造成的。由于硫基含量高,所得的SOGG黏附性越强,所以以巯基的含量作为指标,对合成SOGG的反应条件进行了简单的优化。为了提高巯基含量,通过文献调查及预实验进一步筛选出对酰胺化反应影响较大的三个因素:EDC/NHS的比例、反应pH和L-cys加入量,并对这三个影响因素行条件优化。The initial thiol content after amidation reaction was 47.67 μmol/g, and the thiol group content was relatively low. This may be due to the long molecular chain of OGG and low molecular mobility, making it difficult for L-cys to connect to the OGG main chain. Caused. Due to the high sulfur group content, the resulting SOGG has stronger adhesion, so the reaction conditions for synthesizing SOGG were simply optimized using the sulfhydryl group content as an indicator. In order to increase the sulfhydryl content, three factors that have a greater impact on the amidation reaction were further screened out through literature surveys and preliminary experiments: the ratio of EDC/NHS, reaction pH and the amount of L-cys added, and conditions were determined for these three influencing factors. optimization.
4.2.3.1巯基接枝率条件筛选4.2.3.1 Screening of conditions for thiol grafting rate
4.2.3.1.1不同EDC/NHS比例对巯基含量的影响4.2.3.1.1 Effect of different EDC/NHS ratios on sulfhydryl content
控制反应的pH=5.5,投料比为1:7,改变EDC/NHS的比例,EDC起活化羧基的作用,NHS有固定羧基的作用。由图5a可知,随着EDC/NHS的比例增加,巯基含量由191.3μmol/g增加至332.18μmol/g。当EDC/NHS=5:1,此时巯基含量达到最高。这可能是因为NHS固定羧基与活化后的羧基相结合,跟L-cys有竞争关系。实验尝试不添加NHS,结果并没有EDC/NHS=5:1时巯基含量高。所以根据巯基含量选择EDC/NHS=5:1时进行酰胺化反应。Control the pH of the reaction = 5.5, the feed ratio is 1:7, and change the ratio of EDC/NHS. EDC acts to activate the carboxyl group, and NHS acts to fix the carboxyl group. It can be seen from Figure 5a that as the ratio of EDC/NHS increases, the thiol content increases from 191.3 μmol/g to 332.18 μmol/g. When EDC/NHS=5:1, the sulfhydryl content reaches the highest level. This may be because the NHS fixed carboxyl group combines with the activated carboxyl group and competes with L-cys. The experiment tried not to add NHS, but the result was that the sulfhydryl content was not as high as when EDC/NHS=5:1. Therefore, EDC/NHS=5:1 is selected according to the sulfhydryl content for amidation reaction.
4.2.3.1.2不同pH对巯基含量的影响4.2.3.1.2 Effect of different pH on sulfhydryl content
改变酰胺化反应的pH,其他条件保持不变。由图5b可知,当反应pH由4.0增加至6.0时,巯基含量出现先增加后降低的情况。当pH=5.5时,巯基含量达到最高为204.4μmol/g,说明本实验在pH为5.5的条件下有利于酰胺化反应的进行。Change the pH of the amidation reaction while keeping other conditions unchanged. It can be seen from Figure 5b that when the reaction pH increases from 4.0 to 6.0, the sulfhydryl content first increases and then decreases. When pH=5.5, the thiol content reached the highest level of 204.4 μmol/g, indicating that this experiment is conducive to the amidation reaction under the condition of pH 5.5.
4.2.3.1.3不同投料比对巯基含量的影响4.2.3.1.3 Effect of different feeding ratios on sulfhydryl content
不同投料比即为OGG/L-cys的质量比,改变L-cys的投入量,其他反应条件不变。由图5c的结果可知,随着L-cys的投入量增多,巯基含量出现先增加后减小的情况。当投料比为1:7时,游离巯基含量最高为252.09μmol/g,这可能与L-cys和OGG之间的碰撞有关。当L-cys加入的量增多时,溶液浓度变大,分子与分子间碰撞机会变大,生成产物变多;随着L-cys的再逐步变多,会抑制反应的进程,导致生成的产物减少。Different input ratios are the mass ratio of OGG/L-cys. When the input amount of L-cys is changed, other reaction conditions remain unchanged. It can be seen from the results in Figure 5c that as the input amount of L-cys increases, the thiol content first increases and then decreases. When the feeding ratio was 1:7, the free thiol content was the highest at 252.09 μmol/g, which may be related to the collision between L-cys and OGG. When the amount of L-cys added increases, the solution concentration becomes larger, the chance of collision between molecules increases, and more products are generated; as the amount of L-cys gradually increases, the process of the reaction will be inhibited, resulting in the generation of products. reduce.
综上所述,以SOGG的巯基含量为指标进行单因素反应条件筛选,最后筛选出EDC/NHS=5:1,pH=5.5,投料比为1:7作为最佳反应条件。通过Ellman法计算游离巯基含量:332.18μmol/g,总巯基含量:618.128μmol/g,有46.26%的巯基发生自氧化成二硫键。游离的巯基具有黏附作用,可在LGG与肠粘液之间起到桥梁作用。与此同时,二硫键可以自氧化形成二硫键,可在微球的制备过程中起到交联作用。In summary, the single-factor reaction conditions were screened using the sulfhydryl content of SOGG as an indicator, and finally EDC/NHS = 5:1, pH = 5.5, and a feed ratio of 1:7 were selected as the optimal reaction conditions. The free sulfhydryl group content was calculated by Ellman method: 332.18 μmol/g, the total sulfhydryl group content: 618.128 μmol/g, and 46.26% of the sulfhydryl groups were self-oxidized into disulfide bonds. Free sulfhydryl groups have an adhesive effect and can serve as a bridge between LGG and intestinal mucus. At the same time, disulfide bonds can auto-oxidize to form disulfide bonds, which can play a cross-linking role during the preparation of microspheres.
4.3LGG微球4.3LGG microspheres
4.3.1LGG微球的制备条件筛选4.3.1 Screening of preparation conditions of LGG microspheres
4.3.1.1SOGG浓度对包埋率的影响4.3.1.1 Effect of SOGG concentration on embedding rate
从图6a可知,微球的包埋率随SOGG的浓度增加,呈先增加后减小的趋势。当SOGG浓度为0.5%时,微球的包埋率最大为57.67%。当SOGG浓度不断增加时,包埋率降低。这主要由于当SOGG浓度变大时,多糖溶液粘度增大,导致LGG不易均匀分散在溶液中。当SOGG浓度降低时,形成的微球粒径变小、机械强度低,不能有效地包埋益生菌,影响包埋效果。当SOGG浓度从0%增至2%时,微球粒径逐渐增大,这主要是由于多糖溶液黏度增大,在制备微球过程中不利于乳化,导致微球粒径变大。综上所述,制备LGG微球的最佳SOGG浓度为0.5%。It can be seen from Figure 6a that the embedding rate of microspheres increases first and then decreases as the concentration of SOGG increases. When the SOGG concentration is 0.5%, the embedding rate of microspheres is maximum 57.67%. When the SOGG concentration continues to increase, the entrapment rate decreases. This is mainly because when the concentration of SOGG increases, the viscosity of the polysaccharide solution increases, making it difficult for LGG to be evenly dispersed in the solution. When the concentration of SOGG decreases, the particle size of the formed microspheres becomes smaller and the mechanical strength is low, and the probiotics cannot be effectively embedded, affecting the embedding effect. When the SOGG concentration increased from 0% to 2%, the particle size of the microspheres gradually increased. This was mainly due to the increase in the viscosity of the polysaccharide solution, which was not conducive to emulsification during the preparation of microspheres, resulting in an increase in the particle size of the microspheres. In summary, the optimal SOGG concentration for preparing LGG microspheres is 0.5%.
4.3.1.2SA/CaCO3比例对包埋率的影响4.3.1.2 Effect of SA/CaCO 3 ratio on embedding rate
微球的包封效果与SA与CaCO3的质量比密切相关。在H+存在下,CaCO3会产生Ca2+,生成的Ca2+与SA螯合成胶,因此SA/CaCO3质量比的高低都会影响微球的包埋效果。由图6b可以看出,随着质量比的不断增加,微球的包埋率先增加后减小。当质量比为1:1时,CaCO3浓度较低,有剩余的SA未与Ca2+交联成胶。此时微球不易成型、粒径较大且有黏连、微球壁薄、机械强度小,因此对益生菌在胃内的保护效果较差。随着质量比的增加,反应中Ca2+增多,可以更充分地与SA进行交联,因此益生菌的包埋率逐渐增加,同时形成微球的粒径逐渐变小,呈圆球形、结构紧密、无黏连,可以加强对益生菌的保护。当其质量比为1:4时,益生菌微球的包埋率达到最高为43.38%。但随着质量比的继续增加,Ca2+过剩,CaCO3不能全部与H+反应,微球的粒径开始增加,呈球形不佳,且包埋率开始下降。综上所述,制备LGG微球的最佳SA/CaCO3比例为1:4。The encapsulation effect of microspheres is closely related to the mass ratio of SA to CaCO3 . In the presence of H + , CaCO 3 will produce Ca 2+ , and the generated Ca 2+ will chelate with SA to form a gel. Therefore, the mass ratio of SA/CaCO 3 will affect the embedding effect of microspheres. It can be seen from Figure 6b that as the mass ratio continues to increase, the embedding of microspheres first increases and then decreases. When the mass ratio is 1:1, the CaCO 3 concentration is low, and there is remaining SA that is not cross-linked with Ca 2+ to form a gel. At this time, the microspheres are not easy to form, have large particle sizes and are adherent, have thin walls, and have low mechanical strength, so the protective effect on probiotics in the stomach is poor. As the mass ratio increases, Ca 2+ increases in the reaction and can be more fully cross-linked with SA. Therefore, the entrapment rate of probiotics gradually increases, and the particle size of the formed microspheres gradually becomes smaller, taking on a spherical shape and structure. Tight and non-adhesive, it can enhance the protection of probiotics. When the mass ratio is 1:4, the encapsulation rate of probiotic microspheres reaches a maximum of 43.38%. However, as the mass ratio continues to increase, there is excess Ca2 + , CaCO3 cannot all react with H + , the particle size of the microspheres begins to increase, the spherical shape is poor, and the embedding rate begins to decrease. In summary, the optimal SA/ CaCO ratio for preparing LGG microspheres is 1:4.
4.3.1.3水油比对包埋率的影响4.3.1.3 Effect of water-oil ratio on embedding rate
在微球的制备过程中,乳化起到关键作用。水油体积比可以影响微球的粒径进而影响微球质量。如图6c可知,当油相体积逐渐增多时,微球的包埋率呈现先上升后下降的趋势。当水油体积比为1:1时,油相中产生较大的分散液滴,制备的微球粒径大、微球壁较薄、机械强度低容易破裂,因此包埋率较低。这可能是由于乳化剂的含量较少,形成的微球含量相对较高,在搅拌过程中微球互相碰撞挤压,使得微球成球难。当水油体积比为1:3时,包埋率最高为34.41%,此时微球成球型好,无黏连。随着油相的增多,微球分散空间宽松,使得水相能充分乳化,微球的粒径也逐渐变小,有利于提高微球的包埋率。微球粒径过小,会使益生菌暴露在微球外,同时经过搅拌、离心等机械作用下,微球易破裂,最终导致包埋率较低。综上所述,LGG微球制备的最佳水油体积比为作为1:3。In the preparation process of microspheres, emulsification plays a key role. The water-oil volume ratio can affect the particle size of microspheres and thus the quality of microspheres. As shown in Figure 6c, when the oil phase volume gradually increases, the embedding rate of microspheres shows a trend of first increasing and then decreasing. When the water-to-oil volume ratio is 1:1, larger dispersed droplets are produced in the oil phase. The prepared microspheres have large particle sizes, thin microsphere walls, low mechanical strength and are easy to break, so the embedding rate is low. This may be due to the low content of emulsifier and the relatively high content of microspheres formed. During the stirring process, the microspheres collide and squeeze each other, making it difficult for the microspheres to form into balls. When the volume ratio of water to oil is 1:3, the embedding rate is the highest at 34.41%. At this time, the microspheres have a good spherical shape and no adhesion. As the oil phase increases, the dispersion space of the microspheres becomes looser, allowing the water phase to be fully emulsified, and the particle size of the microspheres gradually becomes smaller, which is beneficial to improving the embedding rate of the microspheres. If the particle size of the microspheres is too small, the probiotics will be exposed outside the microspheres. At the same time, the microspheres will easily break under mechanical action such as stirring and centrifugation, resulting in a low encapsulation rate. In summary, the optimal water-to-oil volume ratio for LGG microsphere preparation is 1:3.
4.3.1.4冰醋酸用量对包埋率的影响4.3.1.4 Effect of glacial acetic acid dosage on embedding rate
冰醋酸与碳酸钙反应释放Ca2+,对SA成胶起关键作用。冰醋酸使用过少,不利于SA成胶,不易制备微球;使用过多,pH酸性太强,会造成益生菌的死亡。所以筛选出既可以成球又不导致益生菌死亡的冰醋酸用量非常重要。如图6d所示,随着冰醋酸用量的增多,包埋率呈先增加后减小的趋势。当冰醋酸的加入量为0.2mL时,冰醋酸的用量少导致有剩余的碳酸钙,使得微球粒径变大,机械强度较弱,所以包埋率较低。当冰醋酸的加入量为0.3mL时,包埋率达到最大为81.56%,此时微球粒径大小均匀,成球型好,机械强度高。随着冰醋酸用量的逐渐增加,包埋率开始下降,即为包埋后的活菌数下降,这是由于过多未与碳酸钙反应的冰醋酸使整个体系的pH降低,致使大多数益生菌死亡。综上所述,制备LGG微球最佳冰醋酸的加入量为0.3mL。Glacial acetic acid reacts with calcium carbonate to release Ca 2+ , which plays a key role in SA gel formation. If too little glacial acetic acid is used, it is not conducive to SA gel formation and it is difficult to prepare microspheres; if too much is used, the pH will be too acidic, which will cause the death of probiotic bacteria. Therefore, it is very important to select the amount of glacial acetic acid that can form balls without causing the death of probiotics. As shown in Figure 6d, as the amount of glacial acetic acid increases, the embedding rate first increases and then decreases. When the added amount of glacial acetic acid is 0.2 mL, the small amount of glacial acetic acid results in residual calcium carbonate, which makes the particle size of the microspheres larger and the mechanical strength is weak, so the embedding rate is low. When the added amount of glacial acetic acid is 0.3 mL, the embedding rate reaches a maximum of 81.56%. At this time, the microspheres have uniform particle size, good spherical shape, and high mechanical strength. As the dosage of glacial acetic acid gradually increases, the encapsulation rate begins to decrease, that is, the number of viable bacteria after embedding decreases. This is because too much glacial acetic acid that has not reacted with calcium carbonate lowers the pH of the entire system, resulting in the loss of most probiotics. Bacteria die. In summary, the optimal amount of glacial acetic acid to prepare LGG microspheres is 0.3 mL.
4.3.1.5正交试验4.3.1.5 Orthogonal test
该正交实验在上述四个单因素实验的基础上进行,选取了SOGG浓度、SA/CaCO3质量比、水油体积比和冰醋酸用量对LGG微球包埋率影响较大的因素,作为自变量,测定微球的包埋率,通过正交实验得到LGG微球的最佳制备工艺条件。以包埋率为指标,极差越大表明该因素对包埋率的影响越大。由表5可知,四种因素对包埋率影响大小依次为:D(冰醋酸的用量)>C(水油体积比)>A(SOGG的浓度)>B(SA/CaCO3的质量比)。因此A1B1C2D2为最佳配方,由于该配方未出现在正交实验列表中,需要进一步进行验证。This orthogonal experiment was conducted on the basis of the above four single-factor experiments, and the factors that had a greater impact on the embedding rate of LGG microspheres were selected: SOGG concentration, SA/CaCO 3 mass ratio, water-to-oil volume ratio, and glacial acetic acid dosage. The independent variable is to measure the embedding rate of microspheres, and obtain the optimal preparation process conditions of LGG microspheres through orthogonal experiments. Taking the embedding rate as an indicator, the larger the range, the greater the impact of this factor on the embedding rate. It can be seen from Table 5 that the impact of the four factors on the embedding rate is as follows: D (amount of glacial acetic acid) > C (water to oil volume ratio) > A (concentration of SOGG) > B (mass ratio of SA/CaCO 3 ) . Therefore, A 1 B 1 C 2 D 2 is the best formula. Since this formula does not appear in the orthogonal experiment list, further verification is required.
表5微球配方筛选的L9(34)正交试验结果Table 5 L 9 (3 4 ) orthogonal test results of microsphere formula screening
根据最佳配方的验证试验表明,A1B1C2D2组合的包埋率较高,达到(88.67±6.8)%,经检验A1B1C2D2的包埋率显著高于其他组(P<0.05)。且微球成球性好,粒径较小。因此,选择A1B1C2D2组合的微球进行下一步实验。以包埋率为指标,则SOGG的质量分数为0.5%,SA/CaCO3的质量比为1:3,水油体积比1:3,冰醋酸的用量为0.3mL,作为LGG微球的最佳配方做后续试验的验证。The verification test based on the optimal formula shows that the embedding rate of the A 1 B 1 C 2 D 2 combination is relatively high, reaching (88.67±6.8)%. After testing, the embedding rate of A 1 B 1 C 2 D 2 is significantly higher than other groups (P<0.05). Moreover, the microspheres have good sphericity and small particle size. Therefore, the microspheres with the combination of A 1 B 1 C 2 D 2 were selected for the next experiment. Taking the encapsulation rate as an indicator, the mass fraction of SOGG is 0.5%, the mass ratio of SA/ CaCO3 is 1:3, the volume ratio of water to oil is 1:3, and the dosage of glacial acetic acid is 0.3mL. As the optimal amount of LGG microspheres, The optimal formula will be verified by subsequent tests.
4.3.2LGG微球外观形态4.3.2 Appearance and morphology of LGG microspheres
通过普通光学显微镜和扫描电子显微镜观察湿微球和冷冻干燥后的微球形态,结果如图7所示。由图7a可知,冷冻干燥后的LGG微球肉眼观察为白色的粉末。由图7b普通光学显微镜观察可知,LGG微球具有表面光滑的规则球形结构,平均粒径为294.46±31.8μm。The morphology of wet microspheres and freeze-dried microspheres was observed by ordinary optical microscope and scanning electron microscope, and the results are shown in Figure 7. As can be seen from Figure 7a, the freeze-dried LGG microspheres are white powder when observed with the naked eye. It can be seen from the ordinary optical microscope observation in Figure 7b that LGG microspheres have a regular spherical structure with a smooth surface and an average particle size of 294.46±31.8 μm.
由图7c、图7d扫描电子显微镜观察可知,微球冷冻干燥后,球体表面出现褶皱,凹陷,球体变为梭形,这是冷冻干燥常见的现象。将微球局部进一步放大观察,能通过红色箭头明显观察到有些益生菌微微隆起包埋在球体内部,有些益生菌黏附在微球的表面,说明有少数益生菌在微球表面。From the scanning electron microscope observation in Figure 7c and Figure 7d, it can be seen that after the microspheres are freeze-dried, wrinkles and depressions appear on the surface of the spheres, and the spheres become spindle-shaped, which is a common phenomenon in freeze-drying. When the microsphere is further magnified and observed, it can be clearly seen through the red arrow that some probiotics are slightly raised and embedded inside the sphere, and some probiotics adhere to the surface of the microsphere, indicating that there are a small number of probiotics on the surface of the microsphere.
4.3.3LGG微球对模拟胃肠液的耐受性4.3.3 Tolerance of LGG microspheres to simulated gastrointestinal fluid
探究游离LGG和LGG微球在模拟胃肠道条件下的生存能力。如图8a结果显示,游离LGG在模拟胃液中孵育2h后,活菌数目显著减少,菌落数减少近7个Log。在模拟肠液中孵育4h后,菌落数减少近0.2个Log可以忽略不计。大量的研究表明,绝大多数益生菌在进入人体胃肠道会显著丧失生活性。随后研究了LGG微球在模拟胃肠液中的耐受性,如图8b所示,在分别经历2h模拟胃液、4h模拟肠液的孵育后,包埋后的LGG活菌数量轻微降低近0.7个Log、0.2个Log,对模拟胃肠液表现出较强的耐受力。说明微球对益生菌起到了一定的保护作用。在探究LGG微球对模拟胃肠液的耐受性之前,为了避免包埋过程对益生菌本身的活性产生影响,研究了包埋前后益生菌的活性是否发生变化。通过绘制包埋后的LGG生长曲线得到,包埋前后的LGG的生长曲线无明显差异。说明微球的包埋过程对LGG活性几乎无影响。To explore the viability of free LGG and LGG microspheres under simulated gastrointestinal conditions. As shown in Figure 8a, the number of viable bacteria decreased significantly after free LGG was incubated in simulated gastric juice for 2 hours, and the number of colonies decreased by nearly 7 Logs. After incubation in simulated intestinal fluid for 4 hours, the number of colonies decreased by nearly 0.2 Log, which was negligible. A large number of studies have shown that most probiotics will significantly lose their activity after entering the human gastrointestinal tract. The tolerance of LGG microspheres in simulated gastrointestinal fluid was then studied. As shown in Figure 8b, after incubation in simulated gastric fluid for 2 hours and simulated intestinal fluid for 4 hours, the number of viable LGG bacteria after encapsulation was slightly reduced by nearly 0.7. Log, 0.2 Log, showing strong tolerance to simulated gastrointestinal fluid. This shows that the microspheres have a certain protective effect on probiotics. Before exploring the tolerance of LGG microspheres to simulated gastrointestinal fluid, in order to avoid the impact of the encapsulation process on the activity of the probiotics themselves, we studied whether the activity of the probiotics changed before and after encapsulation. It was obtained by plotting the growth curve of LGG after embedding. There was no significant difference in the growth curve of LGG before and after embedding. This shows that the embedding process of microspheres has almost no effect on the activity of LGG.
4.3.4LGG微球在模拟连续胃肠液的耐受性4.3.4 Tolerance of LGG microspheres in simulated continuous gastrointestinal fluid
进一步模拟了连续胃肠液对游离LGG和LGG微球的影响,图9进一步表明了微球对LGG的保护作用。与生理盐水组相比,游离的LGG在连续模拟胃肠液中,几乎无活菌存在(P<0.0001)。相比之下,LGG微球包埋的益生菌在胃肠液中连续孵育6h。与对照组相比仅减少0.5个Log。这些结果证实了微球对LGG在胃肠液中有非常重要的保护作用,尽可能的减少胃酸对益生菌造成的损伤。The effect of continuous gastrointestinal fluid on free LGG and LGG microspheres was further simulated, and Figure 9 further demonstrates the protective effect of microspheres on LGG. Compared with the normal saline group, free LGG had almost no viable bacteria in the continuous simulated gastrointestinal fluid (P<0.0001). In contrast, probiotics embedded in LGG microspheres were continuously incubated in gastrointestinal fluid for 6 h. Compared with the control group, it was only reduced by 0.5 Log. These results confirm that microspheres have a very important protective effect on LGG in gastrointestinal fluid and minimize the damage caused by gastric acid to probiotic bacteria.
4.3.5黏附性实验4.3.5 Adhesion test
4.3.5.1LGG与膜的黏附性4.3.5.1 Adhesion between LGG and membrane
为了考察SA/CaCO3微球对LGG的黏附作用,将SA分别与GG、OGG和SOGG制备形成复合薄膜,可以间接验证SOGG对LGG的黏附性。LGG与四种不同膜的粘附性实验结果如图10可知。由图10a可见,单一SA膜的机械性能较其他三组差。其中SA/SOGG膜的机械性能最好,这可能与SOGG中的二硫键自氧化形成的二硫键增强了薄膜的机械强度。由图10b可知,SA膜、SA/GG膜、SA/OGG膜和SA/SOGG膜对LGG均有一定的黏附作用,其中SA/SOGG膜对LGG的黏附率高于其他三组,表明SOGG与LGG之间的相互作用最强,对LGG有更强的黏附作用。说明巯基的引入增加了GG与LGG之间的黏附性。其他三种膜对LGG也同样有黏附性,可能是因为多糖结构上的羟基或羧基与LGG上的基团形成氢键。此外,将四种不同的薄膜浸泡在水中相同时间后,SA/SOGG薄膜相对而言仍保持完整,表明二硫键增强了膜的机械强度。SOGG可以通过与肠道黏液和LGG的双重黏附作用,在肠黏液中起桥梁作用,最终将LGG黏附定植在肠黏膜中。In order to examine the adhesion of SA/CaCO 3 microspheres to LGG, SA was prepared with GG, OGG and SOGG to form composite films, which can indirectly verify the adhesion of SOGG to LGG. The experimental results of adhesion between LGG and four different films are shown in Figure 10. As can be seen from Figure 10a, the mechanical properties of the single SA film are worse than those of the other three groups. Among them, the SA/SOGG film has the best mechanical properties, which may be due to the fact that the disulfide bonds formed by the auto-oxidation of the disulfide bonds in SOGG enhance the mechanical strength of the film. It can be seen from Figure 10b that SA film, SA/GG film, SA/OGG film and SA/SOGG film all have a certain adhesion effect on LGG. Among them, the adhesion rate of SA/SOGG film on LGG is higher than that of the other three groups, indicating that SOGG and The interaction between LGG is the strongest, and it has a stronger adhesion effect on LGG. It shows that the introduction of thiol groups increases the adhesion between GG and LGG. The other three membranes are also adhesive to LGG, probably because the hydroxyl or carboxyl groups on the polysaccharide structure form hydrogen bonds with the groups on LGG. In addition, after the four different films were immersed in water for the same time, the SA/SOGG film remained relatively intact, indicating that the disulfide bonds enhanced the mechanical strength of the film. SOGG can play a bridging role in intestinal mucus through dual adhesion with intestinal mucus and LGG, and ultimately adhere and colonize LGG in the intestinal mucosa.
4.3.5.2肠道粘附性4.3.5.2 Intestinal adhesion
采用外翻肠囊法对微球与肠道的黏附性进行测定,由实验结果黏附率计算可得,结肠粘液对SOGG/SA微球和GG/SA微球的黏附率分别为77.67%和46.17%。由结果可知,结肠对SOGG/SA微球和GG/SA微球均显示出一定的黏膜黏附性,主要是由于结肠黏膜上存在大量绒毛,这些绒毛有助于微球更好地黏附在结肠黏膜及上皮细胞。与此同时结肠部位杯状细胞含量较多,结肠黏膜的黏蛋白水平较高,进一步又增加了微球在结肠部位的黏附性。可能是由于多糖链上的羟基或氨基与粘液糖蛋白上的基团形成了氢键或离子键。小鼠结肠黏膜对SOGG/SA微球的黏附性明显高于对GG/SA微球的黏附性,主要原因可能是由于SOGG/SA微球表面的游离巯基与结肠黏膜分泌的粘液糖蛋白上的巯基反应形成二硫键,进一步增加了微球的黏膜黏附性。The adhesion between the microspheres and the intestine was measured using the everted intestinal sac method. Based on the adhesion rate calculation from the experimental results, the adhesion rates of colonic mucus to SOGG/SA microspheres and GG/SA microspheres were 77.67% and 46.17, respectively. %. It can be seen from the results that the colon shows a certain degree of mucosal adhesion to both SOGG/SA microspheres and GG/SA microspheres, mainly due to the presence of a large number of villi on the colon mucosa, which help the microspheres to better adhere to the colon mucosa. and epithelial cells. At the same time, there are more goblet cells in the colon and higher mucin levels in the colon mucosa, which further increases the adhesion of the microspheres in the colon. It may be due to the formation of hydrogen or ionic bonds between the hydroxyl or amino groups on the polysaccharide chain and the groups on the mucus glycoprotein. The adhesion of mouse colon mucosa to SOGG/SA microspheres is significantly higher than that to GG/SA microspheres. The main reason may be that the free sulfhydryl groups on the surface of SOGG/SA microspheres interact with the mucus glycoprotein secreted by the colon mucosa. The sulfhydryl reaction forms a disulfide bond, further increasing the mucosal adhesion of the microspheres.
4.3.6体内安全性评价4.3.6 In vivo safety evaluation
如图11所示,健康小鼠在连续灌胃LGG微球7d后,小鼠体重保持稳定持续正常增长。与空白组相比,实验组小鼠的精神状态和活动状态几乎无差异。As shown in Figure 11, after 7 days of continuous intragastric administration of LGG microspheres to healthy mice, the weight of the mice remained stable and continued to grow normally. Compared with the blank group, there was almost no difference in the mental state and activity status of the mice in the experimental group.
随后将小鼠处死,收集小鼠的心、肝、脾、肺、肾进行HE染色病理分析。如图12所示,经LGG微球灌胃后的小鼠各内脏组织结构与未灌胃组小鼠没有显著区别,各组织均未检测出明显的炎症反应现象。以上结果表明,LGG微球的体内毒性忽略不计,这有利于LGG微球在体内应用。The mice were then sacrificed, and their hearts, livers, spleens, lungs, and kidneys were collected for HE staining pathological analysis. As shown in Figure 12, the structure of the internal organs of the mice after intragastric administration of LGG microspheres was not significantly different from that of the mice in the non-administered group, and no obvious inflammatory reaction was detected in any tissue. The above results show that the in vivo toxicity of LGG microspheres is negligible, which is beneficial to the in vivo application of LGG microspheres.
应用例1实施例1制备的鼠李糖乳杆菌微球治疗DSS诱导的结肠炎小鼠Application of Lactobacillus rhamnosus microspheres prepared in Example 1 to treat DSS-induced colitis mice
1、实验动物1. Experimental animals
选用SPF级的4-6周龄左右的C57BL/6J雄性小鼠,购买于济南维通利华。SPF grade C57BL/6J male mice about 4-6 weeks old were used and purchased from Jinan Vitong Lever.
2、实验方法2. Experimental methods
2.1结肠炎小鼠模型构建2.1 Construction of colitis mouse model
在动物造模前,将C57BL/6J小鼠在动物喂养7d适应环境。小鼠自由饮用3% DSS溶液7d,建立结肠炎模型,DSS溶液每隔1d更换一次,同时进行治疗观察。小鼠灌胃从造模当天饮用DSS进行,每天灌胃一次,尽量选择同一时间点进行灌胃,每次0.2mL菌液。正常组与DSS模型组分别予以相应体积的生理盐水。Before animal modeling, C57BL/6J mice were fed for 7 days to adapt to the environment. The mice drank 3% DSS solution freely for 7 days to establish a colitis model. The DSS solution was replaced every 1 day while treatment was observed. The mice were given DSS on the day of modeling, and the mice were given DSS once a day. Try to choose the same time point for the intragastric administration, with 0.2 mL of bacterial solution each time. The normal group and DSS model group were given corresponding volumes of physiological saline respectively.
DSS的配制:将DSS溶于灭菌蒸馏水中配成3%(w/v)溶液。Preparation of DSS: Dissolve DSS in sterile distilled water to prepare a 3% (w/v) solution.
实验动物模型建立:将48只小鼠随机分为4组:Control组、DSS组、游离LGG组、LGG微球组,每组12只,分组情况如下:Establishment of experimental animal model: 48 mice were randomly divided into 4 groups: Control group, DSS group, free LGG group, and LGG microsphere group, with 12 mice in each group. The grouping conditions are as follows:
Control组:仅灌胃0.2mL灭菌生理盐水Control group: only 0.2mL sterile saline was administered intragastrically
DSS组:饮用DSS+灌胃0.2mL灭菌生理盐水DSS group: Drinking DSS + intragastric administration of 0.2mL sterile saline
游离LGG组:饮用DSS+灌胃0.2mL 2×109cfu/mL菌悬液Free LGG group: Drinking DSS + intragastric administration of 0.2mL 2×10 9 cfu/mL bacterial suspension
LGG微球组:饮用DSS+灌胃0.2mL LGG微球悬液(实施例1制备的性能最优的微球)LGG microsphere group: drinking DSS + intragastric administration of 0.2 mL LGG microsphere suspension (microspheres with the best performance prepared in Example 1)
2.2小鼠的DAI评价2.2 DAI evaluation of mice
在实验过程中,观察并记录小鼠的精神状态、饮食饮水、活动、排便情况、毛色、体重变化以及死亡情况等。如表6所示,以小鼠体重降低百分比、粪便性状和隐血检测(邻联甲苯胺法)三项评分的平均值作为疾病活动指数(Diseaseactivityindex,DAI),根据小鼠状态及DAI评分初步判断给药效果。During the experiment, the mice's mental state, food and water, activities, defecation, coat color, weight changes, and death were observed and recorded. As shown in Table 6, the average of the three scores of mouse weight loss percentage, fecal characteristics and occult blood detection (o-toluidine method) was used as the disease activity index (DAI), and the preliminary judgment was based on the mouse status and DAI score. Drug administration effect.
DAI=(体重降低评分+大便性状评分+便血程度评分)/3DAI = (weight loss score + stool character score + blood in stool score)/3
表6小鼠DAI评分标准Table 6 Mouse DAI scoring criteria
2.3小鼠结肠组织采集、长度测量及HE染色2.3 Mouse colon tissue collection, length measurement and HE staining
每日多次观察小鼠状态,当DSS组小鼠80%以上出现肉眼便血时,处死小鼠剖开腹腔,肛门口至盲肠之间部分为结肠,测量长度。用预冷PBS溶液冲洗残留的粪便及血液,滤纸吸干水分。将结肠分为两部分,一部分用于HE染色和免疫组化染色,取肛门往上1cm处的结肠浸泡于多聚甲醛中,送样;通过HE染色结果,进行组织学评分;一部分用于髓过氧化物酶的测定,标本迅速转移至-80℃冰箱中保存用于后续实验,避免反复冻融。The status of the mice was observed several times a day. When more than 80% of the mice in the DSS group showed gross blood in their stools, the mice were sacrificed and their abdominal cavities were opened. The colon was measured between the anal opening and the cecum. Wash the remaining feces and blood with pre-cooled PBS solution, and absorb the water with filter paper. The colon was divided into two parts. One part was used for HE staining and immunohistochemical staining. The colon 1cm above the anus was soaked in paraformaldehyde and sent for sample. The HE staining results were used for histological scoring. The other part was used for marrow. For peroxidase determination, the specimens were quickly transferred to a -80°C refrigerator and stored for subsequent experiments to avoid repeated freezing and thawing.
表7结肠组织学评分Table 7 Colon histological scores
2.4小鼠脾脏变化2.4 Changes in mouse spleen
小鼠颈椎脱臼法处死解剖后,取脾脏,称量脾脏的重量,根据脾系数公式计算脾脏系数。After the mice were sacrificed by cervical dislocation and dissected, the spleen was removed, the weight of the spleen was measured, and the spleen coefficient was calculated according to the spleen coefficient formula.
脾系数(%)=(脾脏重量/小鼠体重)*100%Spleen coefficient (%)=(spleen weight/mouse weight)*100%
2.5结肠组织髓过氧化物酶的检测2.5 Detection of myeloperoxidase in colon tissue
用PBS缓冲溶液冲洗结肠组织及内部的粪便,将结肠组织剪碎,用组织研磨机充分研磨,组织匀浆尽量均匀,不要有大块组织存在,制成5%的组织匀浆,实验步骤根据南京建成生物工程研究所的试剂盒说明书操作。通过测定460nm处的吸光度值测定,根据公式计算MPO酶的活力,单位为U/g湿重。Rinse the colon tissue and the feces inside with PBS buffer solution. Cut the colon tissue into pieces and grind it fully with a tissue grinder. The tissue homogenate should be as uniform as possible without large pieces of tissue. Make a 5% tissue homogenate. The experimental steps are as follows: Kit instructions from Nanjing Jiancheng Bioengineering Institute. By measuring the absorbance value at 460nm, the activity of MPO enzyme is calculated according to the formula, and the unit is U/g wet weight.
MPO活力=(A测定-A对照)/(11.3×W)MPO activity=(A measurement -A control )/(11.3×W)
式中:11.3为斜率的倒数;A为460nm处的吸光度值;W为样品取样量。In the formula: 11.3 is the reciprocal of the slope; A is the absorbance value at 460nm; W is the sample sampling volume.
2.6小鼠结肠免疫组化分析2.6 Immunohistochemical analysis of mouse colon
实验操作步骤同2.3,进行结肠组织送样。The experimental steps are the same as 2.3, and colon tissue samples are sent.
3、结果与讨论3. Results and discussion
3.1小鼠一般情况观察3.1 Observation of general conditions of mice
经过7天自由引用3%的DSS诱导小鼠结肠炎。分别观察各组小鼠在实验过程中的体征变化,以下为各组结果:Colitis was induced in mice after 7 days of ad libitum administration of 3% DSS. Observe the physical changes of mice in each group during the experiment. The following are the results of each group:
(1)正常组(Control组):有1只小鼠体重下降较快,可能是由于灌胃过程中食道受损,导致其体重下降。其余11只小鼠饮食、饮水、粪便颜色和形状均正常,毛色光滑,精神活跃。(1) Normal group (Control group): One mouse lost weight rapidly, which may be due to damage to the esophagus during gastric administration, resulting in weight loss. The remaining 11 mice had normal diet, drinking water, and feces color and shape, with smooth coat color and active spirit.
(2)模型组(DSS组):整个实验过程中,12只小鼠均无死亡,实验3-4天,小鼠出现不同程度的扎堆聚集、毛发粗糙,并伴有轻微的腹泻;实验5-7天,小鼠饮水、饮食变少,第5天开始有20%小鼠出现精神萎靡、反应欠灵活、竖毛拱背、稀便等症状;随着实验时间增加,小鼠腹泻加重,肛门口可见血迹,上述症状加剧。当DSS组的小鼠80%以上出现肉眼便血情况即可进行下一步实验。(2) Model group (DSS group): During the entire experiment, none of the 12 mice died. On the 3-4th day of the experiment, the mice appeared in varying degrees of clustering, rough hair, and mild diarrhea; Experiment 5 On the -7th day, the mice drank less water and ate less. On the 5th day, 20% of the mice showed symptoms such as listlessness, inflexible reactions, piloerection, and loose stools. As the experimental time increased, the mice's diarrhea worsened. Blood stains can be seen in the anal opening, and the above symptoms are aggravated. When more than 80% of the mice in the DSS group show gross blood in their stools, the next experiment can be carried out.
(3)游离LGG组(DSS+LGG组):实验开始1-5天,小鼠各项体征均正常。第5-7天,稍有厌食和慵懒的现象,30%粪便略微变稀,但无出现大面积的腹泻,未出现便血情况。小鼠的精神状态及状况均优于正常组。(3) Free LGG group (DSS+LGG group): 1-5 days after the start of the experiment, all physical signs of the mice were normal. On the 5th to 7th day, there was slight anorexia and laziness, and 30% of the feces became slightly thinner, but there was no large-scale diarrhea or blood in the stool. The mental state and condition of the mice were better than those of the normal group.
(4)LGG微球组(DSS+Microsphere组):小鼠在实验过程中均未死亡,实验1-6天与正常组无明显差异,第6天有10%的小鼠粪便略微变稀,但无出现大面积的腹泻,未出现便血情况。小鼠的精神状态及状况均优于正常组及游离LGG组。(4) LGG microsphere group (DSS+Microsphere group): None of the mice died during the experiment. There was no significant difference between the 1-6 days of the experiment and the normal group. On the 6th day, 10% of the mice's feces became slightly thinner. However, there was no widespread diarrhea or blood in the stool. The mental state and condition of the mice were better than those of the normal group and the free LGG group.
3.2小鼠体重变化3.2 Changes in mouse body weight
为了研究游离LGG和包埋后的LGG微球对小鼠对结肠炎小鼠的影响,实验期间每日都记录各组小鼠的体重变化。结果如图13所示,空白组小鼠的体重呈现逐渐增长的趋势,DSS组、DSS+LGG组和DSS+LGG微球组在均呈现下降趋势。DSS组小鼠从第5d开始体重显著下降,差异具有统计学意义(P<0.001)。与DSS组小鼠体重相比,DSS+LGG组和DSS+LGG微球组小鼠的体重下降的相对较慢,同时,LGG微球组的治疗效果相对较好,稀便数量减少,差异具有统计学意义(P<0.01)。结果表明,LGG微球对结肠炎小鼠有一定的治疗作用。In order to study the effects of free LGG and embedded LGG microspheres on mice with colitis, the body weight changes of mice in each group were recorded every day during the experiment. The results are shown in Figure 13. The weight of the mice in the blank group showed a gradual increase trend, while the DSS group, DSS+LGG group and DSS+LGG microsphere group all showed a downward trend. The weight of mice in the DSS group decreased significantly from the 5th day, and the difference was statistically significant (P<0.001). Compared with the weight of mice in the DSS group, the weight of mice in the DSS+LGG group and DSS+LGG microsphere group decreased relatively slowly. At the same time, the treatment effect of the LGG microsphere group was relatively better, with a reduced number of loose stools. The difference was: Statistical significance (P<0.01). The results showed that LGG microspheres had a certain therapeutic effect on colitis mice.
3.3小鼠的DAI评价3.3 DAI evaluation of mice
实验过程中,每天记录各组小鼠体重下降百分比、大便性状、隐血检查结果,进行DAI评分评估。如图14所示,随着实验时间延长,DSS组小鼠DAI不断升高。在第5d部分DSS组小鼠肉眼可见粪便稀便且便血、精神萎靡等症状;与DSS+LGG组、DSS+微球组相比,从第5d开始显著改善小鼠DAI升高。结果表明,LGG和LGG微球均能有效降低结肠炎小鼠DAI评分,其中包埋后的益生菌效果更佳,说明LGG微球比游离LGG对结肠炎治疗效果好。During the experiment, the weight loss percentage, stool characteristics, and occult blood test results of mice in each group were recorded every day, and the DAI score was evaluated. As shown in Figure 14, as the experimental time prolongs, the DAI of mice in the DSS group continues to increase. On the 5th day, the mice in the DSS group could see symptoms such as loose stools, blood in the stool, and lethargy. Compared with the DSS+LGG group and the DSS+microsphere group, the increase in DAI in mice was significantly improved from the 5th day. The results showed that both LGG and LGG microspheres could effectively reduce the DAI score of mice with colitis, and the effect of encapsulated probiotics was better, indicating that LGG microspheres were more effective in treating colitis than free LGG.
3.4结肠长度和病理学损伤评价3.4 Colon length and pathological damage evaluation
如图15a所示,DSS组的结肠长度明显变短,而经过LGG和LGG微球治疗后的小鼠的结肠长度有显著明显变长,说明两者对结肠炎治疗均有一定疗效。与此同时,DSS+LGG组与DSS+LGG微球组的结肠长度有显著性差异。如图15b所示,经H&E染色后,空白组小鼠结肠状态良好,含有大量的杯状细胞,肠上皮和隐窝结构完整且排列有序,没有炎症细胞浸润。DSS组小鼠结肠大量黏膜上皮细胞坏死糜烂,粘膜层和下层可见大量炎细胞浸润,杯状细胞数量明显减少几乎没有并且肠隐窝结构受损,DSS组结肠组织损伤评分显著高于空白组;LGG及LGG微球干预后,结肠黏膜溃疡、糜烂情况明显减轻或消失,杯状细胞排列恢复正常,均显降低了结肠病理评分。此外,LGG微球组与LGG组组织学评分相比,显著改善结肠粘膜损伤,以上结果均说明,LGG微球对结肠炎的治疗效果较未包埋的LGG好。As shown in Figure 15a, the length of the colon of the DSS group was significantly shorter, while the length of the colon of mice treated with LGG and LGG microspheres was significantly longer, indicating that both have certain effects on the treatment of colitis. At the same time, there was a significant difference in the length of the colon between the DSS+LGG group and the DSS+LGG microsphere group. As shown in Figure 15b, after H&E staining, the colon of the mice in the blank group was in good condition, containing a large number of goblet cells, the intestinal epithelium and crypt structures were intact and orderly, and there was no inflammatory cell infiltration. A large number of mucosal epithelial cells in the colon of mice in the DSS group were necrotic and eroded, a large number of inflammatory cells were infiltrated in the mucosal layer and lower layer, the number of goblet cells was significantly reduced and the intestinal crypt structure was damaged. The colon tissue damage score of the DSS group was significantly higher than that of the blank group; After the intervention of LGG and LGG microspheres, the ulcers and erosions of the colon mucosa were significantly reduced or disappeared, and the arrangement of goblet cells returned to normal, all of which significantly reduced the colon pathology score. In addition, compared with the histological score of the LGG group, the LGG microsphere group significantly improved the colon mucosal damage. The above results all show that the LGG microsphere has a better therapeutic effect on colitis than unembedded LGG.
3.5小鼠脾脏变化3.5 Changes in mouse spleen
由图16可知,DSS组的脾脏系数增加明显,随着游离LGG和LGG微球治疗,脾脏系数均下降。说明游离益生菌和包埋后的益生菌对结肠炎均有一定的治疗作用。经过LGG微球治疗后的小鼠与空白组几乎无显著差异,说明LGG微球可以缓解DSS诱导造成的脾系数变大,对结肠炎有一定的治疗作用。As can be seen from Figure 16, the spleen coefficient of the DSS group increased significantly, and with the treatment of free LGG and LGG microspheres, the spleen coefficient decreased. This shows that both free probiotics and embedded probiotics have certain therapeutic effects on colitis. There was almost no significant difference between mice treated with LGG microspheres and the blank group, indicating that LGG microspheres could alleviate the enlargement of the spleen coefficient induced by DSS and have a certain therapeutic effect on colitis.
3.6结肠组织髓过氧化物酶的检测3.6 Detection of myeloperoxidase in colon tissue
由图17可知,DSS组小鼠的结肠组织MPO酶活力显著高于正常组。经过LGG和LGG微球治疗的介入,小鼠与正常组无显著性差异,说明两者对结肠炎均有一定的治疗作用。但LGG微球组与LGG组存在显著性差异(P<0.05),LGG微球组对结肠炎治疗效果佳。As shown in Figure 17, the MPO enzyme activity in the colon tissue of mice in the DSS group was significantly higher than that in the normal group. After the intervention of LGG and LGG microsphere treatment, there was no significant difference between the mice and the normal group, indicating that both have a certain therapeutic effect on colitis. However, there was a significant difference between the LGG microsphere group and the LGG group (P<0.05). The LGG microsphere group had a better therapeutic effect on colitis.
3.7小鼠结肠免疫组化分析3.7 Immunohistochemical analysis of mouse colon
由图18知,黄棕色为阳性蛋白,与空白组相比,当经过DSS刺激诱导IL-10的含量显著下调,这表明DSS组小鼠结肠中含有大量中性粒细胞浸润,炎症严重。当经过治疗之后,LGG和LGG微球都能显著上调DSS刺激分泌减少的结肠IL-10含量。可以看出,LGG和LGG微球可以通过上调IL-10含量从而缓解结肠炎症,其中LGG微球组上调效果最为明显。As can be seen from Figure 18, yellow-brown color is a positive protein. Compared with the blank group, the IL-10 content is significantly down-regulated when stimulated by DSS. This indicates that the colon of mice in the DSS group contains a large number of neutrophils infiltrating and the inflammation is severe. After treatment, both LGG and LGG microspheres could significantly increase the content of colonic IL-10, which was stimulated by DSS and decreased secretion. It can be seen that LGG and LGG microspheres can alleviate colon inflammation by up-regulating IL-10 content, among which the LGG microsphere group has the most obvious up-regulation effect.
小鼠结肠中IL-6、TNF-α含量由图18可知,对照组小鼠结肠中IL-6、TNF-α含量较低,当用DSS刺激后,IL-6和TNF-α含量显著增加。当用LGG和LGG微球进行治疗后均不同程度下调了DSS刺激而分泌上升的IL-6和TNF-α的含量,且与DSS组相比都有显著性差异。从图18可以看出,LGG和LGG微球都能通过下调IL-6和TNF-α含量从而降低肠道炎症,且LGG微球组的改善效果最为显著。The contents of IL-6 and TNF-α in the colon of mice can be seen from Figure 18. The contents of IL-6 and TNF-α in the colon of mice in the control group were low. When stimulated with DSS, the contents of IL-6 and TNF-α increased significantly. . When treated with LGG and LGG microspheres, the levels of IL-6 and TNF-α secreted increased by DSS stimulation were reduced to varying degrees, and there were significant differences compared with the DSS group. As can be seen from Figure 18, both LGG and LGG microspheres can reduce intestinal inflammation by down-regulating the levels of IL-6 and TNF-α, and the improvement effect of the LGG microsphere group is the most significant.
以上所述仅为本发明的优选实施例而已,并不用于限制本发明,对于本领域的技术人员来说,本发明可以有各种更改和变化。凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。The above descriptions are only preferred embodiments of the present invention and are not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and changes. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention shall be included in the protection scope of the present invention.
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310640431.3A CN116725958A (en) | 2023-05-30 | 2023-05-30 | A kind of thiolated oxidized guar gum/sodium alginate microsphere and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310640431.3A CN116725958A (en) | 2023-05-30 | 2023-05-30 | A kind of thiolated oxidized guar gum/sodium alginate microsphere and its preparation method and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116725958A true CN116725958A (en) | 2023-09-12 |
Family
ID=87903711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310640431.3A Pending CN116725958A (en) | 2023-05-30 | 2023-05-30 | A kind of thiolated oxidized guar gum/sodium alginate microsphere and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116725958A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118806729A (en) * | 2024-06-18 | 2024-10-22 | 海南合瑞制药股份有限公司 | Mesalazine enteric-coated sustained-release pellets and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130338099A1 (en) * | 2010-09-09 | 2013-12-19 | Bioregen Biomedical (Changzhou) Co., Ltd. | Mercapto-modified biocompatible macromolecule derivatives with low degree of mercapto-modification and the cross-linked materials and uses thereof |
| CN105748417A (en) * | 2016-04-15 | 2016-07-13 | 广州创赛生物医用材料有限公司 | Preparation method of novel sulfhydrylated nanoparticles based on guar gum/cysteine conjugates |
| CN112094790A (en) * | 2020-11-17 | 2020-12-18 | 招远新兴化工有限公司 | Lactobacillus plantarum LP45 live bacterium preparation for regulating intestinal flora and application thereof |
-
2023
- 2023-05-30 CN CN202310640431.3A patent/CN116725958A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130338099A1 (en) * | 2010-09-09 | 2013-12-19 | Bioregen Biomedical (Changzhou) Co., Ltd. | Mercapto-modified biocompatible macromolecule derivatives with low degree of mercapto-modification and the cross-linked materials and uses thereof |
| CN105748417A (en) * | 2016-04-15 | 2016-07-13 | 广州创赛生物医用材料有限公司 | Preparation method of novel sulfhydrylated nanoparticles based on guar gum/cysteine conjugates |
| CN112094790A (en) * | 2020-11-17 | 2020-12-18 | 招远新兴化工有限公司 | Lactobacillus plantarum LP45 live bacterium preparation for regulating intestinal flora and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| ZHANG ET AL.: "Injectable in situ dual-crosslinking hyaluronic acid and sodium alginate based hydrogels for drug release", 《J BIOMATER SCI POLYM ED》, vol. 30, no. 12, 14 May 2019 (2019-05-14) * |
| 张永 等编著: "《纳米纤维素的基础与应用》", 31 October 2022, 黑龙江大学出版社, pages: 79 - 80 * |
| 杨新建 等: "基于海藻酸钠的复合壁材包被嗜酸乳杆菌及其效果评估", 《饲料工业》, vol. 40, no. 22, 31 December 2019 (2019-12-31), pages 1 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118806729A (en) * | 2024-06-18 | 2024-10-22 | 海南合瑞制药股份有限公司 | Mesalazine enteric-coated sustained-release pellets and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Charge-reversible and biodegradable chitosan-based microgels for lysozyme-triggered release of vancomycin | |
| Abbasi et al. | Novel biodegradable pH-sensitive hydrogels: An efficient controlled release system to manage ulcerative colitis | |
| CN114099696B (en) | Nano-selenium sodium alginate composite gel and preparation method and application thereof | |
| CN113041232B (en) | Oral colon targeting hydrogel for targeting intestinal tract blasting and preparation method and application thereof | |
| CN105007759B (en) | Metal ion-functional fiber component complex composition, its preparation and use | |
| Huang et al. | A double-layer polysaccharide hydrogel (DPH) for the enhanced intestine-targeted oral delivery of probiotics | |
| CN116139073B (en) | Inflammation targeting hydrogel loaded with antioxidant nano particles and preparation method thereof | |
| CN115361963B (en) | Biocomposite materials comprising probiotics, collagen and bacterial exopolysaccharides and uses thereof | |
| Lin et al. | Polydopamine-cladded montmorillonite micro-sheets as therapeutic platform repair the gut mucosal barrier of murine colitis through inhibiting oxidative stress | |
| Wang et al. | A thiolated oxidized guar gum and sodium alginate dual-network microspheres with enhanced gastric acid resistance and mucoadhesion for delivery of probiotics | |
| CN118557525A (en) | A microsphere with dual responsiveness and high adhesion based on microfluidics and its preparation method and application | |
| Chen et al. | Oral Delivery of Transformable Bilirubin Self‐Assembled System for Targeted Therapy of Colitis | |
| Zhang et al. | Biocompatible, adhesive and stable GelMAc/PVAMA/MPDA@ Cur hydrogels regulate immune response to improve endoscopic submucosal dissection-induced gastric ulcer healing in vivo | |
| CN116725958A (en) | A kind of thiolated oxidized guar gum/sodium alginate microsphere and its preparation method and application | |
| CN116637084A (en) | A kind of melanin nanoparticle microcapsule and its preparation method and application | |
| Ding et al. | An ROS/DAMP dual-scavenging nanomedicine for normalizing macrophage polarization and microbiome in colitis | |
| Zhang et al. | A dual-polysaccharide (carboxylated chitosan-carboxymethyl cellulose sodium) gastrointestinal dynamic response in situ hydrogel for optimized oral targeted inflammatory bowel disease therapy | |
| Nishiguchi et al. | Inflammation-targeting polyamine nanomedicines for the treatment of ulcerative colitis | |
| Wang et al. | Orally-administrable supramolecular probiotic capsules enable cooperative colon-targeted inflammation inhibition for ameliorating ulcerative colitis | |
| CN118599716A (en) | Bifidobacterium breve TG030 for inhibiting colon cancer pathogenic bacteria Fusobacterium nucleatum and its application | |
| CN113388554A (en) | Lactobacillus plantarum SHY130 and application thereof in relieving diabetes | |
| CN117018024B (en) | A selenized chitosan functionalized bismuth-based metal compound, preparation method and application | |
| CN116172997B (en) | Application of phenyllactic acid in inhibiting Helicobacter pylori infection | |
| CN116617156A (en) | Novel intelligent magnetic drive probiotic KGM/SA bionic roundworm gel | |
| CN120114398B (en) | Multiple response colon inflammation targeting hydrogel microsphere and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |